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harbor a population of HIV-specific CD160+2B4+ CD8 T-cells associated with perforin not commonly
present in CP. This indicates that coexpression of CD160 and 2B4 delineates a population of cytolytic CD8 T-
cells important for the control of HIV in blood. However this association is not present in LN CD8 T-cells
indicating differential regulation of cytolytic factors within these tissues.
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ABSTRACT 
EXPRESSION OF PD-1, CD160 AND 2B4 ON CD8 T CELLS DURING 
HIV INFECTION: MARKERS OF EXHAUSTION? 
Carolina Pombo 
Michael R. Betts 
HIV infection is typically associated with dysfunction of the immune system.  
Evidence indicates that CD8 T-cells are crucial in the fight against HIV, but with disease 
progression CD8 T-cells become functionally exhausted rendering them unable to control 
viral replication and spread. Unlike chronically infected individuals (CP), HIV elite 
controllers (EC) retain CD8 T-cell polyfunctionality and killing function.  These 
characteristics have been linked to the ability of EC to suppress viral replication to 
undetectable levels without therapy intervention. It remains unclear whether EC manifest 
T-cell exhaustion similar to CP, and whether exhaustion level measured in blood is 
representative of that in lymphatic tissues, a site of persistent viral replication.  Current 
antiretroviral therapies successfully reduce viral replication to undetectable levels in 
blood, but fail to eliminate the viral reservoir within lymph nodes (LN), highlighting the 
importance in developing means to reinvigorate immune responses in these tissues. 
To date, studies focusing on T-cell exhaustion use a lack of IL-2, IFNγ and TNF 
together with co-expression of inhibitory receptors to define exhausted populations.  
However, these studies fail to address conflicting data on the role of these receptors as 
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markers of activation and their involvement in cytolytic activity, a known correlate of 
protection against HIV in elite controllers. To address this, we assembled a cohort of EC, 
CP and healthy individuals and simultaneously measured expression PD-1, Lag-3, 
CD160 and 2B4, cytokines IFNγ and TNF, and cytolytic molecule perforin. We also 
compared CD8 T-cell exhaustion in blood and LN in a cohort of HIV+ individuals on and 
off ART.   
We report that EC have a high proportion of potentially exhausted 
(PD1+CD160+2B4+) HIV-specific CD8 T-cells comparable to that in CP, a population 
also present in HIV+ LN on and off ART.  However, EC also harbor a population of 
HIV-specific CD160+2B4+ CD8 T-cells associated with perforin not commonly present 
in CP. This indicates that coexpression of CD160 and 2B4 delineates a population of 
cytolytic CD8 T-cells important for the control of HIV in blood. However this association 
is not present in LN CD8 T-cells indicating differential regulation of cytolytic factors 
within these tissues. 
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CHAPTER 1: Introduction 
Pathogenesis of the Human Immunodeficiency Virus 
 The Human Immunodeficiency Virus (HIV) was identified in 1983 from a lymph 
node of an individual with lymphadenopathy by two separate groups (Barré-Sinoussi et 
al., 2004; Gallo et al., 1983).  It was later determined that HIV is the causative agent of 
Acquired Immunodeficiency Syndrome (AIDS).  Since its discovery 35 years ago, 
approximately 40 million people have died of AIDS related causes.  According to data 
collected by the World Health Organization (WHO), there are currently 35 million people 
living with HIV world wide, including 3.2 million children.  If left untreated, the majority 
of HIV-infected individuals, known as chronic progressors (CP), will develop gradual 
immunodeficiency that results in an increased risk of opportunistic infections and tumors 
7–10 years, on average, after infection.  Despite great efforts by WHO and other 
organizations to distribute antiretroviral therapy in an effort to slow the epidemic, there 
were 2.1 million new infections and 1.5 millions deaths world wide in 2013. 
HIV is an enveloped retrovirus, a member of the genus Lentivirus, from the 
family Retroviridae (Gonda, 1988).  The viral particle contains two copies of positive 
single-stranded RNA that encodes three major polyproteins: gag (spliced into capsid 
protein P24, matrix protein P17 and nucleocapsid P15), pol (spliced into protease, reverse 
transcriptase, integrase), and env (envelope protein spliced into gp120 and gp41) 
(Sundquist & Kräusslich, 2012).  The viral genome also codes for regulatory elements 
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involved in viral replication (tat, rev, vpr) and immune modulation (vif, nef) (Arhel et al., 
2009; Sundquist & Kräusslich, 2012).   
HIV entry into target cells is mediated by interactions between the viral envelope 
protein (env) and both the T-cell receptor CD4 and a chemokine receptor, either CCR5 or 
CXCR4. Upon entry, viral cDNA is synthesized from viral RNA by reverse transcriptase 
and transported into the nucleus where it is integrated into the host DNA by the viral 
protein integrase.  The viral reverse transcriptase is prone to errors providing the virus 
with a high mutation rate that allows rapid evolution and escape from competent immune 
detection and elimination (Boutwell, Rolland, Herbeck, Mullins, & Allen, 2010; Richman 
et al., 2004).  
During acute infection, HIV primarily infects activated CD4+ T-cells in gut-
associated lymphoid tissues (GALT) leading to rapid depletion of this population.  As 
disease progresses, HIV dissemination to peripheral lymphoid tissues coupled with 
immune activation contribute to destruction of lymphoid tissue architecture, disruption of 
homeostatic processes that maintain T cell numbers and antigen presentation (Brenchley 
et al., 2004).  Progressive loss of CD4 T-cells also extends to peripheral blood 
contributing to immunodeficiency and disease progression. CD4 T-cell depletion is partly 
due to direct killing of infected cells, but it is exacerbated by production of pro-
inflammatory cytokines such as IFNγ and TNF that induce activation and death of 
uninfected by-stander CD4 T-cells (Brenchley et al., 2004; Groux et al., 1992).  
Furthermore, structural damage to GALT tissues leads to translocation of microbial 
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products from the gut lumen into systemic circulation, further contributing to general 
immune activation.  As a consequence of prolonged antigen stimulation and immune 
activation, T cells gradually become less effective at fighting not only HIV but also other 
opportunistic infections, leading to the onset of AIDS.  
However, a small subset of HIV-infected individuals, referred to as elite 
controllers (EC), is capable of suppressing viral replication to very low levels without the 
need for antiretroviral therapy.  Understanding the factors involved in maintenance of 
chronic disease and differences in the CD8+ T-cell response between pathogenic and 
non-pathogenic infection may provide insights into correlates of immune protection, 
thereby informing the development of HIV vaccines and immunotherapeutic strategies.  
Elite control of HIV has been attributed to host factors that impede viral 
replication and reduce systemic immune activation.  A 32-base pair deletion within the 
CCR5 gene (CCR5-Δ32) results in a reduction of surface expression of this receptor.  
Individuals homozygous for this mutation are protected from infection with HIV viruses 
requiring use of CCR5 co-receptor for entry.  Individuals heterozygous for CCR5-Δ32 
have lower viral set-point and experience slower disease progression (Baker, Block, 
Rothchild, & Walker, 2009).  Elite control of HIV is also associated with high expression 
cellular intrinsic factors such as APOBEC3G and TRIM5α, both part of the innate 
immune response to infection (Baker et al., 2009).  In addition, expression of the natural 
killer (NK) cell receptor KIR3DS1 was shown to significantly reduce viral replication 
(O'Connell, Han, Williams, Siliciano, & Blankson, 2009).  Expression of certain HLA 
4 
 
alleles, such as HLA-B57 and HLA-B27, are associated with viral escape mutations 
associated with diminished replicative fitness (Bailey, Brennan, O'Connell, Siliciano, & 
Blankson, 2008; Miura et al., 2009).  There is also evidence from studies looking at 
pathogenic and non-pathogenic HIV and SIV infection of non-human primates that CD8 
T-cells play an important role in controlling viral replication (Bailey et al., 2008; Betts et 
al., 2006; Grabar et al., 2009; Hersperger et al., 2010; Migueles et al., 2002; 2008; Sáez-
Cirión et al., 2007)  
Innate Immunity and HIV Infection 
The innate immune system is the first line of defense against viral infection.  
During the initial stages of HIV infection, innate immunity has an important role in viral 
control but can also contribute to disease pathology.  Cell intrinsic factors such as Toll-
like Receptors (TLRs) and restriction factors (APOBEC3, TRIM5a, SAMHD1 and 
Tetherin) interfere with viral replication as spread by recognizing viral RNA and trigger 
production of type-I interferons that interfere with viral replication, maturation and 
budding from the host cell (Reviewed in (Altfeld & Gale, 2015)).  Production of pro-
inflammatory cytokines and chemokines lead to activation of monocytes, macrophages 
and dendritic cells (DC). Macrophages and DCs then travel to lymph nodes where they 
activate the adaptive immune response by presenting antigen to T cells. However, high 
levels of IFNα trigger apoptosis of CD4 T-cells in GALT, further contributing to disease 
progression (Baker et al., 2009). HIV uses DCs and macrophages as vehicles in to lymph 
nodes, providing the virus with a target rich environment and further contributing to viral 
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spread.  Once infected cells reach lymphatic tissues, HIV induces a reduction of motility 
allowing formation of virological synapses for better cell-to-cell spread, establish the 
viral reservoir and disrupt lymph node structure, further contributing to immune 
dysfunction (Arhel et al., 2009; Baxter et al., 2014; Nasr, Harman, Turville, & 
Cunningham, 2014).  
Activation of natural killer (NK) cells is triggered by multiple activating and 
inhibitory receptors that allow detection of infected cells that downregulate MHC-I.  In 
response to pro-inflammatory stimuli, NK cells migrate to the site of infection where they 
release cytolytic molecules (perforin and granzymes) for direct killing of infected cells 
(Gosselin, TomoIu, Gallo, & Flamand, 1999).  NK cells in elite controllers have a higher 
cytotoxic capacity compared to progressors despite having similar expression of 
inhibitory and activating receptors (O'Connor, Holmes, Mulcahy, & Gardiner, 2007).  
Expression of specific killer cell immunoglobulin like receptors (KIRs) alleles were 
found to correlate with elite control of HIV (discussed above).  NK cells also suppress 
HIV viral replication by production of chemokines RANTES, MIP-1α and MIP-1β, 
which bind to the CCR5 receptor, a co-receptor required for HIV entry into target cells 
(Kottilil et al., 2004; O'Connor et al., 2007).  Deregulation of NK cells during HIV 
infection is evident early after infection by decreased cytotoxic capacity (reduced 
perforin and granzymes) in combination with an aberrant activating and inhibitory 
receptor expression profile (Altfeld, Fadda, Frleta, & Bhardwaj, 2011; Kottilil et al., 
2004). NK cells from viremic individuals have increased expression of inhibitory 
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receptors compared to healthy controls (Mavilio et al., 2003).  Still a number of questions 
related to the role of specific NK inhibitory receptors and their expression patterns in NK 
dysfunction during HIV infection remain unanswered and deservers further study. 
 
Adaptive Immune Responses and HIV Infection 
Humoral Immunity to HIV 
 HIV infection triggers production of a variety of antibodies capable of binding to 
HIV that may or may not be able to interfere with viral spread. The humoral immune 
response to HIV is made up of binding antibodies, neutralizing antibodies and 
monoclonal antibodies with broad neutralizing activity (reviewed in (Baum, 2010)). 
Antibodies that bind to the HIV envelope glycoprotein are capable of neutralizing the 
virus through antibody-dependent cell-mediated viral inhibition (ADCVI) and antibody 
dependent cell-mediated cytotoxicity (ADCC). However high titters of neutralizing 
antibodies are necessary for protection since any unbound HIV env protein can trigger 
infection of a target cell.  Furthermore, the majority of binding antibodies isolated from 
HIV chronic progressors are specific for the initial or “founder” virus (Baum, 2010) but 
are unable to limit HIV spread due to the virus’ rapid evolution away from recognized 
epitopes.  
On the other hand, broadly neutralizing antibodies are specific for conserved 
regions of the viral envelope, such as the CD4 binding region, and are able to neutralize 
most isolates (Baum, 2010; Overbaugh & Morris, 2012). However, these broad 
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neutralizing antibodies take time to emerge and are not present during the initial stages of 
HIV infection (Baum, 2010). Inadequate T cell help provided to B cells in lymph nodes 
as disease progresses affects B cell survival and further contribute to emergence of 
ineffective antibodies against HIV (Cubas et al., 2013).  Great effort is being put into 
developing vaccines capable of inducing broad neutralizing antibodies against HIV, but 
their success remains unclear (Baker et al., 2009; Overbaugh & Morris, 2012; Willis et 
al., 2015). 
HIV-Specific CD4 T-cells 
 During HIV infection, HIV-specific memory CD4 T-cells are 
preferentially infected and killed (Douek et al., 2002), primarily affecting CD4 T cells 
outside lymphoid tissues such as the intestinal mucosa. CD4 T cells are comprised of 
subsets with distinct immunological function including Th1, Th2, Th17, T follicular 
helper (TFH) and T regulatory (Treg). The initial depletion of CD4 T cells is countered by 
homeostatic proliferation of memory CD4 T cells due to immune activation, slowing the 
progressive loss of total CD4 counts. However, this regeneration does not restore all CD4 
T cell populations and it is not stable long term, eventually resulting in the decline CD4 T 
cell numbers (Reviewed in (Okoye & Picker, 2013)). The progressive loss of CD4 T cells 
is used as a measure of disease progression. CD4 T-cells are an essential component of an 
effective immune response, often referred to as T helper cells. CD4 T-cells promote 
immune control by providing help to B cells and CD8 T-cells. Lack of CD4 T cell help 
contributes to dysfunction of B cells and CD8 T-cells and is linked to development of 
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opportunistic infections in AIDS patients (Rosenberg et al., 2000). There is also evidence 
supporting the role of CD4 T-cells in controlling viral replication through direct cytolytic 
activity (Norris et al., 2004), though this might also contribute to CD4 T-cell depletion 
and disease progression.  
Lymph node-resident TFH cells migrate from the T cell zone into B cell follicles 
where they interact with antigen-specific B cells in specialized structures called germinal 
centers, enhancing antibody affinity, maturation and differentiation of follicular B cells 
into memory B cells or plasma cells; initiating the humoral response to HIV infection 
(discussed above). TFH cells are preferentially enriched in HIV+ lymph nodes and are 
believed to serve as viral reservoirs. Efforts focused on eliminating the HIV reservoir are 
concentrated in understanding the regulatory mechanisms of TFH cells as well as other 
lymph node-resident immune cells to determine the best approach to eliminate infected 
cells in the this important anatomical site. Studies to determine the advantages of early 
initiation of ART reported a delayed time to AIDS and maintenance of mucosal CD4 T 
cells preventing microbial translocation and general immune activation (Grinsztejn et al., 
2014; Schuetz et al., 2014). It would be of interest to determine the effect this approach 
would have on lymph node architecture, CD4 T helper function and establishment of the 
HIV reservoir. 
HIV-specific CD8 T-cells 
CD8 T cells are primarily responsible for recognizing host cells that are either 
abnormal or infected by an invading intracellular pathogen. Circulating CD8 T cells that 
9 
 
have not encountered antigen are referred to as naïve CD8 T cells, which are mostly 
quiescent and have little to no effector functions. Upon recognition of antigen through 
interactions between the T cell receptor (TCR) and the MHC-I:peptide complex, along 
with co-stimulatory signals, naïve T-cells differentiate and acquire effector functions 
such as cytokines (e.g. IFNγ, TNF, or IL-2), chemokines (e.g. MIP1α, MIP1β or 
RANTES) or cytolytic molecules (e.g. perforin and granzymes) for direct killing of target 
T-cells.  CD8 T cell responses can therefore be classified into polyfunctional memory 
(IL2+IFNγ+ and other functions) or polyfunctional effector (perforin+IFNγ+ and other 
functions) based on viral specificity (Makedonas et al., 2010). Mature CD8 T-cells are 
highly specific for a limited number of peptide epitopes presented on major 
histocompatibility class I (MHC-I) molecules found on the surface of professional 
antigen presenting cells, abnormal cells or infected cells. 
In the context of HIV infection, the role of CD8 T cells in viral control has been 
inferred by the resolution of peak viremia to a lower set point coincides with CD8+ T-cell 
emergence and elimination infected cells by direct and indirect killing (Gulzar & 
Copeland, 2004). HIV-specific CD8 T-cell responses have been measured even before 
antibodies can be detected during acute HIV infection (Mackewicz, Yang, Lifson, & 
Levy, 1994). Researchers have further characterized this dynamic using SIV infection of 
non-human primates. CD8 T-cell depletion during SIV infection confirmed the critical 
role played by CD8 T-cells in early control of viremia (Jin et al., 1999; Schmitz et al., 
1999).   
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Nevertheless the frequency of HIV-specific T-cells alone is not a correlate of 
immune protection and does not predict disease progression (Betts et al., 2001; Schellens 
et al., 2008). The quality of the CD8 T-cell response is measured by the polyfunctionality 
of individual cells, defined by their capacity to respond to antigen stimulation by 
simultaneously producing multiple effector functions. These functions include the ability 
to proliferate, produce cytolytic molecules (perforin, Granzymes), multiple cytokines (IL-
2, TNFα, IFNγ) and differentiate into memory T-cells. There is evidence suggesting that 
number of T-cells with highly polyfunctional effector responses correlates with immune 
protection of elite controllers during HIV infection (Almeida et al., 2007; Betts et al., 
2001; 2006; Darrah et al., 2007; Gulzar & Copeland, 2004; Precopio et al., 2007; 
Schellens et al., 2008).  But as a consequence of continued exposure to viral antigens and 
immune activation CD8 T-cells gradually lose their functional ability (Wherry et al., 
2007), a process referred to as T-cell exhaustion. As disease progresses into the chronic 
stage, HIV-specific CD8+ T-cells have a decreased ability to proliferate and secrete 
cytokines (Jagannathan et al., 2009).  
 
T-cell Exhaustion 
 After acute viral infection, CD8+ T-cells rapidly activate effector functions and 
have a high proliferative potential.  After antigen burden is resolved, the antigen-specific 
CD8 T-cell population contracts allowing a protective memory population to form and be 
maintained by antigen-independent homeostatic proliferation.  In contrast, during chronic 
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infection the antigen is not cleared and antigen-specific CD8+ T-cells gradually become 
less functional and lose proliferative capacity, leaving them unable to clear the antigen 
(Barber et al., 2006).  The loss of function is hierarchical: proliferation potential and IL-2 
are lost early, TNF persists longer and in extreme cases the last function lost is IFN 
(reviewed in (Wherry, 2011)).  In severe cases, especially when CD4+ help is lacking 
such as during HIV infection, virus-specific CD8+ T-cells fully lacking effector functions 
can be found (Wherry et al., 2007).  
T-cell exhaustion was first described using LMCV infection of mice, where 
CD4+ depleted mice resulted in the most profound CD8+ T-cell exhaustion, but the main 
features of exhaustion were preserved in the presence of CD4+ T-cells (reviewed in (Shin 
& Wherry, 2007)).  T-cell exhaustion has been studied in mice (Blackburn et al., 2008; 
Bucks, Norton, Boesteanu, Mueller, & Katsikis, 2009; Jackson, Berrien-Elliott, Meyer, 
Wherry, & Teague, 2013; Utzschneider et al., 2013), non-human primates (Petrovas et 
al., 2007; Velu et al., 2007) and human subjects suffering from chronic diseases (Bengsch 
et al., 2010; Fourcade et al., 2012; Kroy et al., 2014; Riches et al., 2013; Yamamoto et 
al., 2011).  Though there are differences among the models used, a common 
characteristic of T-cell exhaustion is that it is antigen specific.  HIV+ patients exhibit T-
cell exhaustion on HIV-specific CD8 T-cells but not EBV, FLU or CMV-specific CD8 T-
cells, suggesting that CD8 T-cell responses are determined by the duration and intensity 
of antigenic exposure and could therefore be a consequence of viremia (D'Souza et al., 
2007; Jagannathan et al., 2009; Nakamoto et al., 2008; Petrovas et al., 2006).  
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Furthermore, T-cells maintain an exhausted phenotype after antigen withdrawal and 
population re-expansion, suggesting the exhausted phenotype is passed to daughter cells, 
even when T-cells are no longer exposed to high levels of antigen (Streeck et al., 2008). 
In addition, exhausted T-cells have translational, metabolic and bioenergetic deficiencies 
as well as a cumulative expression of inhibitory receptors (Aldy, Horton, Mathew, & 
Mathew, 2011; Bengsch et al., 2010; Blackburn et al., 2008; Fourcade et al., 2012; Kroy 
et al., 2014; Riches et al., 2013; Wherry et al., 2007; Yamamoto et al., 2011). 
Phenotypic markers of T-cell exhaustion 
Co-stimulatory signals and Inhibitory receptors are important regulators of T-cell 
function, working together to regulate the initiation and termination of effective adaptive 
immune responses. However, the accumulation of inhibitory receptors in the presence of 
persistent antigen can result in the inability to respond upon re-stimulation.  In the last ten 
years a number of studies have shown associations between expression of inhibitory 
receptors and T-cell exhaustion in the setting of chronic disease (Barber et al., 2006; 
Blackburn et al., 2008; Day et al., 2006; Peretz et al., 2012; Tian et al., 2015; Trautmann 
et al., 2006; Utzschneider et al., 2013; Velu et al., 2007). The most common inhibitory 
receptor associated with T cell exhaustion is PD-1.  The transcription profile of exhausted 
LCMV-specific CD8 T cells and phenotype profile of HIV-specific CD8 T cells 
identified other markers upregulated during chronic infection.  Inhibitory receptors 
CD160, 2B4, Lag-3, CTLA-4, PIR-B and GP49b, TIM 3 (Blackburn et al., 2008; 
Odorizzi & Wherry, 2012; Parry et al., 2005; Wherry et al., 2007; Z.-Z. Yang et al., 
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2012). This work focused on on the four inhibitory receptors shown to be strongly 
associated with T cell exhaustion, PD-1, CD160, 2B4 and Lag-3 (Wherry et al., 2007).    
PD-1 
 PD-1 is a member of the immunoglobulin gene superfamily, first identified in two 
lymphoid cell lines as a cell death-associated gene playing a role in programmed cell 
death (Ishida, Agata, Shibahara, & Honjo, 1992).  PD-1 is expressed upon engagement of 
the antigen-receptor on activated T-cells, NK cells, B cells and myeloid cells (Agata et 
al., 1996; Blackburn et al., 2010; Freeman et al., 2000). Several studies in mice 
chronically infected with LCMV clone 13 have demonstrated that engagement of PD-1 
has a negative effect on proliferative expansion, cytokine production and cytotoxicity as 
well as increased sensitivity to apoptosis of virus-specific CD8 T-cells (Barber et al., 
2006; Blackburn et al., 2010; Freeman et al., 2000; Shin & Wherry, 2007; Wherry, 2011).  
Two ligands for PD-1 have been identified, PD-L1 and PD-L2, both members of the B7 
family.  Though non-lymphoid tissues such as lung, heart, placenta and skeletal muscle 
constitutively express varying levels of PD-L1 and PD-L2, IFNγ induces expression of 
these ligands on monocytes (Freeman et al., 2000; Latchman et al., 2001).  Engagement 
of PD-1 by PD-L1 or PD-L2 on target T-cells can suppress effector T-cell function by 
reducing phosphorylation of TCR associated proteins by recruitment of Src homology 2 
(SH2) domain–containing tyrosine phosphatase 2 (SHP2) (Barber et al., 2006; Freeman 
et al., 2000; Latchman et al., 2001; Yokosuka et al., 2012).  Blocking the PD-1/PD-L1 
signaling pathway by using an anti-PD-L1 antibody results in enhanced T-cell responses 
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and restores the proliferation capacity of CD8 T-cells while they continued to express the 
PD-1 receptor, suggesting continuous engagement of PD-1/PD-L1 is necessary for 
inhibition (Barber et al., 2006) 
In the context of HIV infection, a high level of PD-1 expression on HIV-specific 
CD8 T-cells is associated with high viral load and disease progression (D'Souza et al., 
2007; Day et al., 2006; Petrovas et al., 2006; Trautmann et al., 2006; Zhang et al., 2007).  
However, PD-1 expression is also high on EBV-specific CD8 T-cells and these cells are 
not dysfunctional (Petrovas et al., 2006). Furthermore, several reports suggest PD-1 
expression alone is not necessarily a marker of exhaustion, but can serve as a marker of 
T-cell activation and differentiation (Legat, Speiser, Pircher, Zehn, & Fuertes Marraco, 
2013; Zelinskyy et al., 2011), highlighting the importance of measuring multiple 
parameters to determine functional exhaustion.  
CD160 
CD160 was first identified as a GPI-anchored cell surface molecule expressed on 
NK cells, CD8 T-cells and intestinal intraepithelial T lymphocytes (Anumanthan et al., 
1998; Nikolova, Marie-Cardine, Boumsell, & Bensussan, 2002).  An alternative isoform 
of CD160 with a transmembrane domain (CD160-TM) has also been detected in 
activated NK cells.  CD160 is expressed as a disulfide-linked multimer with a broad 
specificity for binding both classical and non-classical MHC class I molecules (Nikolova 
et al., 2002) and a higher affinity to the herpes virus entry mediator (HVEM) receptor 
(Cai et al., 2008). Several reports suggest a dual function for CD160 determined by its 
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binding partner.  Interactions between CD160 and MHC class I molecules enhance CD3-
induced proliferation (Nikolova et al., 2002) and cytotoxicity (Nikolova et al., 2005; Rey 
et al., 2006).  Whereas, interaction between CD160 and HVEM results in an inhibitory 
signal marked by reduced cytokine expression and cytotoxicity (Cai et al., 2008; Kojima, 
Kajikawa, Shiroishi, Kuroki, & Maenaka, 2011). The exact mechanism through which 
CD160 exerts its effect is not fully understood.  However, a soluble form of CD160 
(sCD160)has been detected in culture of activated T cells and has been shown to inhibit 
migration of monocytes and immanure dendritic cells. Generation of sCD160 was shown 
to occur through a metalloprotease-dependent shedding (Giustiniani, Marie-Cardine, & 
Bensussan, 2007). Further insight into the regulatory mechanisms of CD160 expression 
and function are necessary before this marker can be considered a candidate for 
therapeutic development. 
2B4 
 2B4 (CD244) is a member of the CD2 superfamily expressed on NK cells, CD8 
T-cells, thymocytes, monocytes and basophils (Boles, Stepp, Bennett, Kumar, & 
Mathew, 2001).  Several studies have shown that expression of 2B4 correlates with 
effector differentiation (Boles et al., 2001; Legat et al., 2013; McNerney, Lee, & Kumar, 
2005; Rey et al., 2006).  2B4 has dual function depending on levels of expression, 
availability of the SLAM-associated protein (SAP) and degree of cross-linking 
(Chlewicki, Velikovsky, Balakrishnan, Mariuzza, & Kumar, 2008)  Engagement of this 
receptor can lead to an inhibitory or a stimulatory signal.  An inhibitory signal results in a 
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decrease in proliferation, cytolytic activity and production of IFNγ.  On the other hand, 
the stimulatory signal can induce proliferation and potentiate cytolytic activity (Meinke 
& Watzl, 2013). The ligand for 2B4 is CD48, which has a wide distribution in the 
hematopoietic system and is particularly expressed in EBV-infected B lymphocytes (Rey 
et al., 2006).  Similar to CD160, further understanding of the regulatory mechanisms 
involved in defining the function of 2B4 are necessary in order to consider this receptor 
for therapeutic purposes. 
LAG-3 
Lag-3 is a ligand for MHC class II and it is genetically related to CD4 (Hannier, 
Tournier, Bismuth, & Triebel, 1998; Triebel et al., 1990).  Lag-3 is primarily expressed 
on activated CD8 T-cells and to a lesser extent on CD4+ T-cells found in inflamed 
secondary lymphoid organs or tissues and even though it has a high affinity to MHC class 
II it does not disturb CD4-MHC class II interactions (Triebel, 2003).  Cell capping 
experiments demonstrated Lag-3 recruitment to the CD3 complex in lipid rafts after 
antigen recognition where it starts a negative signal cascade that results in reduced 
homeostatic expansion and proliferation of activated T-cells in vivo by preventing entry 
of the T-cell into the cell cycle (Hannier et al., 1998; Workman & Vignali, 2005).  In the 
context of HIV infection, Lag-3 expression by CD8 T-cells from blood of infected 
patients is low (Yamamoto et al., 2011).  However, there is data showing high expression 
of Lag-3 in tissues relevant for HCV infection and tumor microenvironment (Grosso et 
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al., 2007; Kroy et al., 2014; Woo et al., 2012).  There is also evidence of a role for Lag-3 
in exhaustion and disease progression (Okazaki et al., 2011; Tian et al., 2015)  
 
THESIS GOALS 
 Immune dysregulation is a hallmark of HIV infection.  Efforts to reverse T-cell 
exhaustion have concentrated around the inhibitory receptor PD-1.  Studies have shown 
that PD-1 alone is not sufficient to induce T-cell exhaustion. Evidence points to a high 
correlation between high expression of PD-1 and co-expression of inhibitory receptors 
Lag-3, CD160 and 2B4 in exhausted T cells.  Contradicting data establishes CD160 and 
2B4 as both inhibitory and stimulatory, bringing their role in T cell exhaustion into 
question.  In this study we aimed to characterize the expression of PD-1, Lag-3, CD160 
and 2B4 on human CD8 T-cells in the context of HIV infection and determined if these 
receptors truly are markers of T cell exhaustion.  To this end, we measured expression of 
these exhaustion markers along with effector functions previously shown to be correlates 
of immune protection in a cohort of elite controllers and chronic progressors.  
Even with the introduction of antiretroviral therapy immune re-constitution is 
incomplete and interruption of treatment results in a rebound of viral load.  In addition, 
there is evidence of on-going low-level viral replication in subjects fully suppressed by 
ART.  In the last few years there has been a growing effort to identify the source of that 
virus, believed to be TFH cells in germinal centers.  Evidence suggests establishment of 
the viral reservoirs occurs in the lymph nodes during early infection.  However, little is 
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known about the ability of lymph node-resident immune cells to find and kill infected 
cells. Of interest, the ability of lymph node CD8 T cells to recognize and eliminate 
infected TFH cells in germinal centers and/or their exhausted state is yet to be 
determined. To date, most of what we know about T-cell exhaustion is from peripheral 
blood CD8 T-cells.  The second aim of this study was to determine if levels of exhaustion 
observed in CD8 T-cells from blood represent the level of CD8 T cell exhaustion in HIV 
positive lymph nodes. To this end, we measured expression of PD-1, CD160 and 2B4 on 
CD8 T-cells from blood and lymph nodes of HIV+ subjects on and off ART.  At the 
same time, we measured IFNγ, TNF and perforin expression after HIV-specific 
stimulation to identify associations between expression of PD-1, CD160, 2B4 and T cell 
responses. To this day, HIV infection remains incurable due to early establishment of 
viral reservoirs. We hope that the results from this work will aid in the effort to improve 
existing ART and develop new vaccine platforms against HIV.  
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CHAPTER 2: ELITE CONTROLLERS EXPRESS MORE CD160 
AND LESS PD-1 THAN CHRONIC PROGRESSORS 
SUMMARY 
During the chronic phase of HIV infection virus-specific CD8 T-cells lose their 
ability to proliferate, produce multiple cytokines and kill infected cells, a state known as 
T-cell exhaustion. However, unlike chronically infected individuals, HIV elite controllers 
suppress HIV replication without the need for antiretroviral therapy.  Several studies have 
shown that elite controllers also retain CD8 T-cell polyfunctionality and killing function, 
characteristics considered correlates of protection. It remains unclear whether HIV elite 
controllers manifest T-cell exhaustion similar to chronically progressing HIV infected 
subjects. Here we assessed the co-expression of inhibitory markers PD-1, Lag-3, CD160 
and 2B4 in a cohort of HIV elite controller subjects compared to HIV chronic progressors 
as a measure of T-cell exhaustion. We find that elite controllers have a broad range of co-
expression of these inhibitory receptors.  Elite controllers have a significantly higher 
proportion of CD160+2B4+ CD8 T-cells compared to chronic progressors.  Additionally, 
elite controllers have proportion of potentially exhausted (PD1+CD160+2B4+) HIV-
specific CD8 T-cells comparable to that observed in chronic progressors. This work was 
published in (Pombo, Wherry, Gostick, Price, & Betts, 2015) 
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INTRODUCTION 
 Untreated HIV infection is typically a chronic progressive disease associated with 
a gradual and progressive loss of control of viral replication and a steady decline in CD4 
T-cell counts resulting in the collapse of the immune system (Hubert et al., 2000).  
During the early stages of infection CD8 T-cells play and important role in controlling 
viral replication by eliminating infected cells  (reviewed in (Gulzar & Copeland, 2004)), 
but lose this ability as the disease progresses into the chronic stage (reviewed in (El-Far 
et al., 2008)).  However, there is a small subset of HIV infected individuals referred to as 
elite controllers that are capable of suppressing viral replication to very low levels 
without the need for anti-retroviral therapy (ART).  Several studies looking to understand 
differences in CD8 T-cell responses between HIV chronic and elite subjects have shown 
the importance of the cytotoxic CD8 T-cell (CTL) function in suppressing HIV 
replication (O'Connell et al., 2009). However, a better understanding of the degree of T-
cell exhaustion, if any, in elite controllers could further elucidate correlates of immune 
protection and aid in the development of therapies and vaccines. 
Elite controllers are a rare subset (<1%) of HIV infected individuals that have the 
ability to suppress HIV viral replication to undetectable levels (<50 copies/mL) for many 
years without the need for ART.  These individuals have stable CD4 T-cell counts and no 
history of AIDS defining illnesses (Grabar et al., 2009).  A study looking a discordant 
couples with one elite controller and one progressor showed that in both individuals the 
virus is replication competent, and the only difference was the host genetics and immune 
system, suggesting that host genetics and immune responses play a role in elite control 
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(Bailey et al., 2008). Despite maintaining control of viral replication, the presence of HIV 
escape variants with mutations to CTL epitopes is evidence of low-level viral replication 
present within these subjects (Miura et al., 2009) 
T-cell exhaustion has been studied in mice (Blackburn et al., 2008; Bucks et al., 
2009; Jackson et al., 2013; Utzschneider et al., 2013), non-human primates (Petrovas et 
al., 2007; Velu et al., 2007) and human subjects suffering from chronic diseases (Bengsch 
et al., 2010; Fourcade et al., 2012; Kroy et al., 2014; Riches et al., 2013; Yamamoto et 
al., 2011).  Typical markers associated with T-cell exhaustion include PD-1, Lag-3, 
CD160 and 2B4.  Additionally, studies have shown a strong association between high 
levels of PD-1, HIV viral loads and disease progression (Day et al., 2006; Petrovas et al., 
2006; Trautmann et al., 2006). Different patterns of inhibitory receptor expression have 
been shown to identify exhausted populations defined by a decrease in IL-2, TNF and 
IFNγ (Bengsch et al., 2010; Blackburn et al., 2008; Peretz et al., 2012; Rey et al., 2006; 
Viganò et al., 2014; Yamamoto et al., 2011).  However there is also evidence that some 
of these receptors have dual function and can act as co-stimulatory ligands (Meinke & 
Watzl, 2013; Nikolova et al., 2005).  While the majority of previous work has been done 
in the context of chronic progressive disease, the level of exhaustion in the context of 
controlled HIV infection has not been explored. In this study, we assessed the potential 
exhaustion of CD8 T-cells in elite controllers using previously defined markers of 
exhaustion PD-1, Lag-3, CD160 and 2B4.  Our results show lower expression of PD-1 
but higher expression of CD160 on elite controller CD8 T-cells compared to those from 
chronic progressors. Furthermore, elite controllers have a significant fraction of CD8 T-
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cells co-expressing CD160 and 2B4.  Interestingly, elite controllers have a population of 
PD-1+CD160+2B4+ CD8 T-cells previously defined exhausted.  This potentially 
exhaustion population was comparable to that of chronic progressors, a possible 
indication of on-going low-level viral replication within these subjects.   
MATERIALS AND METHODS 
PBMC samples 
Peripheral blood mononuclear cells (PBMC) were obtained from healthy subjects 
at the University of Pennsylvania's Center For AIDS Research Human Immunology Core 
and cryopreserved in fetal bovine serum (FBS; ICS Hyclone, Logan Utah) containing 
10% dimethyl sulfoxide (DMSO; Fisher Scientific, Pittsburgh, Pennsylvania).  PBMCs 
from HIV positive individuals were obtained from three sources in compliance with the 
guidelines set by the respective institutional internal review boards: the University of 
Pennsylvania’s Center for AIDS Research Human Clinical Core Facility and clinics 
associated with Harvard University and the University of Alabama Birmingham. 
Chronic progressors were defined as untreated individuals with HIV plasma RNA 
levels above 2,000 copies/mL (range: 2,319-484,699; median: 10,193) infected for >2 
years.  Elite controllers were defined as therapy naïve individuals with viral loads <75 
HIV RNA copies/mL at multiple time points and infected for >2 years.  All subjects had 
CD4 counts > 200 cells/mm3 and lacked evidence of an AIDS defining illness.  All 
samples were cryopreserved before use. 
Antibodies 
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Antibodies for surface staining included anti-CD4 PE-Cy5.5 (clone S3.5, 
Invitrogen), anti-CD8 Qdot605 (clone 3B5, Invitrogen) or Brilliant Violet 605 (clone 
RPA-T8, Biolegend), anti-CD27 Qdot 655 (clone CLB-27/1, Invitrogen) or Brilliant 
Violet 650 (clone O323, Biolegend), anti-CD45RO ECD (clone UCHL1, Beckman 
Coulter), anti-PD-1 PE (clone EH12.2 H7, Biolegend), anti-CD160 (Cai et al., 2008), 
conjugated in-house) FITC and anti-CD244 (2B4) PE-Cy5 (clone C1.7, Beckman 
Coulter), anti-CD14 APC-AF750 (clone TüK4, Invitrogen), anti-CD19 APC-AF750 
(clone SJ25-C1, Invitrogen), anti-Lag-3 biotin (polyclonal, R&D Systems), Streptavidin-
APC (Invitrogen), and anti-APC biotin (clone eBioAPC-62A, eBiosicience). Intracelluar 
staining: anti-CD3 Qdot 585 (custom conjugation performed in our laboratory as 
previously described (Chattopadhyay et al., 2006) or Brilliant Violet 570 (clone UCHL1, 
Biolegend). 
FACS staining assay 
 After 5 hours of stimulation, cells were washed once with FACS buffer and 
stained for Lag-3 in four steps: First adding anti-Lag-3 biotin (R&D Systems) for 15 
minutes then washed with FACS buffer, next Streptavidin APC (Invitrogen) for 15 
minutes then washed with FACS buffer, followed by addition of anti-APC biotin 
(eBiosicience) for 15 minutes then washed with FACS buffer and finally staining with 
Streptavidin APC for 15 minutes.  After washing with PBS and staining with Aqua 
amine-reactive viability dye (Invitrogen) for 10 minutes to exclude non-viable events, the 
cells were stained for surface markers with an antibody cocktail for an additional 30 
minutes.  Following a wash with FACS buffer, the cells were permeabilized with Cytofix 
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Cytoperm (BD Biosciences) as per manufacturer’s instructions.  Next, a cocktail of 
antibodies against intracellular markers was added and incubated for an hour.  Lastly, the 
cells were washed with Perm Wash Buffer (BD Biosciences) and fixed in PBS containing 
1% paraformaldehyde.  All incubations were done at room temperature in the dark.  
Fixed cells were stored at 4°C until the time of collection.  
Flow cytometric analysis 
 For each sample, between 5x105 and 1x106 total events were acquired on a 
modified flow cytometer (LSRII; BD Immunocytometry systems) equipped for the 
detection of 18 fluorescent parameters and longitudinally standardized for signal 
consistency using the previously described calibration methods (Perfetto, Ambrozak, 
Nguyen, Chattopadhyay, & Roederer, 2012).  Antibody capture beads (BD Biosciences) 
were used to prepare individual fluorophore matched compensation tubes for each 
antibody used in the experiments.  Data analysis was performed using FlowJo version 
9.6.4 (TreeStar, Inc). Reported functional data have been corrected for background. 
Statistical analysis was performed with Prism, version 5.0. Comparison of inhibitory 
receptor expression among cohorts was analyzed using the Mann-Whitney U test. 
Correlation coefficients were calculated using the Spearman rank sum test. All tests were 
2-tailed, and P values less than 0.05 were considered significant 
 
RESULTS 
Elite controllers express less PD-1 but more CD160 than chronic progressors 
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To determine the level of potential T-cell exhaustion present in elite controllers 
(EC) and assess differences from what is known in chronic progressors (CP), we began 
by using the differential expression of CD27 and CD45RO to distinguish between the 
naïve (CD27+CD45RO-) and memory CD8+ T-cell populations (Figure 1A).  Naïve cells 
were then used as reference to determine surface expression of individual exhaustion 
markers PD-1, Lag-3, CD160 and 2B4 (Figure 1B).  Flow cytometry plots showing 
expression of PD-1, Lag-3, CD160 and 2B4 on Naïve and memory CD8 T-cells for an 
HIV negative (HIV-), a CP and an EC are shown in Figure 2.   
Systemic immune activation due to microbial translocation can be a determinant 
of clinical progression in both chronic progressors and elite controllers regardless of 
viremia (León et al., 2015).  Once can hypothesize that the persistent presence of 
microbial products can contribute to exhaustion of the bulk CD8 T-cell compartment. To 
assess this possibility, we measured surface expression of PD-1, Lag-3, CD160 and 2B4 
as markers or exhaustion on total CD8 T-cells. A significantly higher proportion of CD8 
T-cells from elite controllers expressed CD160 compared to both CP and HIV-negative 
subjects but significantly less PD-1 (Figure 3A).  Previous reports linked expression of 
inhibitory receptors on CD8 T-cells to differentiation and activation status, with naïve T-
cells expressing the less than memory T-cells (Legat et al., 2013).  Therefore we 
determined the memory distribution of CD8 T-cells within in the HIV-negative, CP and 
EC groups and compared expression of PD-1, Lag-3, CD160 and 2B4 between naïve and 
memory CD8 T-cells (Figure 3B).  Naïve CD8 T-cells from HIV-negative, CP and EC 
express low levels of PD-1, Lag-3 and 2B4 (mean: <15%), but naïve CD8 T-cells from 
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HIV-negative and EC expressed significantly more CD160 than those from CP (Figure 
4A).  To better compare the EC, CP and HIV- groups we excluded the naïve population 
and continued our analysis focusing on the memory population.   
In accordance to previous reports (Zhang et al., 2007) EC memory CD8+ T-cells 
expressed PD-1 at significantly lower frequencies (mean: 30%) compared to memory 
CD8 T-cells from CP (mean: 45%; p<0.01) and HIV- subjects (mean: 40%; p<0.01) 
(Figure 4B). Furthermore, Lag-3 was expressed at low frequencies on memory CD8 T-
cells (mean: 5-10%) regardless of infection status  (Figure 4B).  Memory CD8 T-cells in 
the EC cohort expressed significantly more CD160 (mean: 58%) compared to CP (mean: 
27%, p<0.01) and HIV- individuals (mean: 32%, p<0.05) (Figure 4B).  On the other 
hand, EC memory CD8 T-cells expressed 2B4 at frequencies comparable to those within 
CP (mean: 84% and 86% respectively) but higher than their HIV- counterparts (mean: 
72%, p<0.001) (Figure 4B).  Differences in the proportion of memory CD8 T-cells 
expressing PD-1 and CD160 between elite controllers and chronic progressors could due 
to differences in differentiation status within the memory pool. 
 
HIV elite controllers express a high frequency of CD160+2B4+ double positive CD8 T-
cells 
 A characteristic of T-cell exhaustion is the co-expression of inhibitory receptors 
on the cell surface (Blackburn et al., 2008; Wherry et al., 2007); therefore we assessed 
co-expression of PD-1, Lag-3, CD160 and 2B4 on total (Figure 5A) and memory CD8 T-
cells (Figure 5B). A majority of the total and memory CD8 T-cells were grouped into 
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four populations: PD-1+Lag3-CD160+2B4+, PD-1-Lag-3-CD160+2B4+, PD-1+Lag-3-
CD160-2B4+ and PD-1-Lag-3-CD160-2B4+.  Differences in frequency between the total 
and memory populations in EC, CP and HIV negative subjects were due to the fraction of 
naïve CD8 T-cells present (data not shown); therefore we continued our analysis on 
memory CD8 T-cells.  EC had a higher frequency of PD-1-Lag-3-CD160+2B4+ memory 
CD8 T-cells compared to CP (p<0.0001) and HIV negative individuals (p<0.0001).  In 
contrast, EC expressed less PD-1+Lag-3-CD160-2B4+ than CP and HIV- subjects 
(p<0.0001) and less PD-1-Lag-3-CD160-2B4+ than CP (p<0.05) (Figure 5B).  We found a 
trend towards a higher frequency of the triple positive (PD-1+CD160+2B4+) population 
previously defined as exhausted (Yamamoto et al., 2011) in HIV positive subjects 
compared to HIV negative subjects, but this trend did not reach statistical significance.   
 
DISCUSSION 
Elite control of HIV infection is generally associated with the increased presence 
of polyfunctional and effector-like CD8 T-cell responses against HIV (Almeida et al., 
2007; Bailey et al., 2008; Betts et al., 2006; Gulzar & Copeland, 2004; Hersperger et al., 
2010).  However, given the chronic nature of infection in these subjects and the continual 
need for effective immunosurveillance to prevent HIV recrudescence, one could 
hypothesize that CD8 T-cells in HIV elite controllers may display some indications of 
CD8 T-cell exhaustion.  Conversely, it is also possible that CD8 T-cell exhaustion does 
not manifest in HIV elite controllers, thus permitting superior longitudinal control of HIV 
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viremia.  Here we began to address these issues by comparing the expression of 
previously identified exhaustion markers (Barber et al., 2006; Day et al., 2006; Doering 
et al., 2012; Trautmann et al., 2006; Zhang et al., 2007) on total and memory CD8 T-cells 
from elite controllers, chronic progressors and HIV negative individuals.  
In line with previous reports, we found that elite controllers express low levels of 
PD-1 compared to chronic progressors.  Low expression of this receptor on the CD8 T 
cell population implies that CD8 T-cells in elite controllers do not experience the same 
level of population-wide exhaustion observed in chronic progressors.  Interestingly, 
expression of CD160 on memory CD8 T-cells from elite controllers was significantly 
higher than in both chronic progressors and HIV negative subjects.  CD160 expression 
has been shown be involved in both CD8 T-cell inhibition and induction of cytotoxicity.  
Since elite control of HIV has been associated with increased cytolytic activity, in the 
context of elite controllers the high expression of CD160 could be a marker for CTL 
activity not inhibition.  Further studies are needed to identify the signaling pathways 
involved in modulating expression and signaling of CD160.   
In the context of T-cell exhaustion in HIV, co-expression of PD-1, CD160 and 
2B4 has been associated with high viral loads and decreased polyfunctionality.  If these 
markers truly define exhaustion, then our data would suggest the presence of a large 
population of exhausted (PD-1+CD160+2B4+) HIV-specific CD8 T-cells in elite 
controllers. Such a population might be indicative on ongoing low-level viral replication 
in lymphatic tissues known to harbor the viral reservoir and difficult to detect in blood.  
Even though elite controllers suppress viral replication to undetectable levels, studies 
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have shown they can experience gradual loss of CD4 T-cells and immune activation due 
to microbial translocation (León et al., 2015; Novati, Sacchi, Cima, & Zuccaro, 2015) 
leading to clinical progression.  The presence of exhausted T-cells in elite controllers 
supports the idea that factors other than viremia drive immune activation than can lead to 
immune dysfunction.     
We also found that elite controllers have significant proportion of CD8 T-cells co-
expressing CD160 and 2B4 not usually observed in chronic progressors.  Both of these 
receptors have been previously associated with increased cytolytic activity.  Co-
expression of these markers in the absence of PD-1 could define a cytolytic population 
within these subjects.  Such a population has been previously associated with elite control 
of HIV viral replication.  In the last few years there has been an increased interest in the 
therapeutic value of blocking PD-1 clinic. These findings would suggest that PD-1 
signaling is disrupting the cytolytic signaling pathway associated with expression of 
CD160 and 2B4, providing a mechanism through which anti-PD-1/PD-L1 therapy works 
to re-invigorate CD8 T cell responses.  Further studies into downstream signaling targets 
of PD-1 engagement are necessary to understand this idea further. 
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Figure 1: Flow cytometry gating scheme  
Flow cytometry gating scheme used on total peripheral blood mononuclear cells 
(PBMCs) to identify (A) memory phenotype and (B) expression of inhibitory receptors. 
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Figure 2: Representative flow cytometry lots of Individual expression of inhibitory 
receptors PD-1, Lag-3, CD160 and 2B4.  
Representative flow cytometry plots showing individual expression of inhibitory 
receptors on naïve and memory CD8 T-cells from an HIV negative, a chronic progressors 
and an elite controller subject.   
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Figure 3:  Individual expression of PD-1, Lag-3, CD160 and 2B4 on total CD8 T-
cells 
(A) The percentage of total CD8 T-cells from HIV-negative (blue circles), CP (red 
circles) and EC (green circles) individuals expressing each receptor. (B) Memory 
distribution of CD8 T-cells from HIV negative (HIV-; blue dots), chronic progressors 
(CP; red dots) and elite controllers (EC; green dots). Error bars represent mean + SEM. 
Dots indicate individual subjects. Statistical analysis was carried out using one-way 
ANOVA tests (nonparametric; Kruskal-Wallis) followed by a Dunns test for multiple 
comparisons. *p<0.05, ** p<0.01, *** p<0.001 
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Figure 4: Individual expression of PD-1, Lag3, CD160 and 2B4 on naïve and 
memory CD8 T-cells.   
(A) The percentage of naïve CD8 T-cells from HIV-negative (HIV-), chronic progressor 
(CP) and elite controllers (EC) expressing individual inhibitory receptors. (B) The 
percentage of memory CD8 T-cells from HIV-negative (HIV-), chronic progressor (CP) 
and elite controllers (EC) individuals expressing each receptor. Error bars represent mean 
+ SEM. Statistical analysis was carried out using one-way ANOVA tests (nonparametric; 
Kruskal-Wallis) followed by a Dunns test for multiple comparisons. ** p<0.01, *** 
p<0.001 
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CHAPTER 3: CO-EXPRESSION OF CD160 AND 2B4 IS 
ASSOCIATED WITH PERFORIN EXPRESSION IN VIRUS-
SPECIFIC CD8 T-CELLS 
SUMMARY 
As discussed in chapter 2, we found that elite controllers have a population of 
potentially exhausted memory CD8 T-cells (PD-1+CD160+2B4+). In addition, we found a 
population of CD160+2B4+memory CD8 T-cells not commonly seen in chronic 
progressors.  Both of these markers are associated with dual function when expressed, 
they are involved in increased cytolytic activity and T-cell exhaustion.  The role of these 
receptors in the context of elite control of HIV infection remains unclear.  To elucidate if 
expression of these markers in elite controllers delineate an exhausted population we 
measured co-expression of PD-1, CD160 and 2B4 together with the cytolytic molecule 
perforin and cytokines IFNγ and TNF on HIV-specific CD8 T-cells from elite controllers 
and compared them to CD8 T-cells from chronic progressors.  We found that elite 
controllers have a proportion of possibly exhausted HIV-specific CD8 T-cells 
comparable to that of chronic progressors.  However, we also found that the 
CD160+2B4+ CD8 T-cells in elite controllers correlates with cytolytic capacity as 
measured by perforin expression.  This double positive a population is not commonly 
found in HIV chronic progressors.  We therefore propose that coexpression of CD160 
and 2B4 delineate a population of CD8 T-cells important in the control of viral 
replication. This work was published in (Pombo et al., 2015) 
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INTRODUCTION 
Cytolytic T lymphocytes (CTL) from elite controllers have a state of low immune 
activation, measured by HLA-DR and CD38, with the capacity for rapid proliferation 
(Sáez-Cirión et al., 2007). Evidence shows that proliferative capacity is linked to 
increased perforin expression, facilitating the killing of infected cells and thus contribute 
to the efficacy of the cytotoxic response (Migueles et al., 2002).  Previous work from our 
lab has shown that CD8 T-cell responses can be classified into polyfunctional memory 
(IL2+IFNγ+ and other functions) or polyfunctional effector (perforin+IFNγ+ and other 
functions) responses based on viral specificity (Makedonas et al., 2010). In the context of 
non-progressive HIV disease, highly functional effector HIV-specific CD8 T-cells are 
preferentially maintained and are an important component in the control of HIV 
replication (Betts et al., 2006; Gea-Banacloche et al., 2000; Hersperger et al., 2010; 
Migueles et al., 2008; Sáez-Cirión et al., 2007). Additional evidence suggests that the 
number of T-cells with a highly polyfunctional effector response correlates with immune 
protection during viral infections (Almeida et al., 2007; Betts et al., 2001; Darrah et al., 
2007; Precopio et al., 2007; Schellens et al., 2008).  Furthermore, the non-human primate 
model of SIV infection supports the role of CD8 T-cells in controlling viral replication, 
where depletion of CD8 T-cells correlates with an increase in SIV viral load and rapid 
disease progression (Jin et al., 1999; Schmitz et al., 1999).  However, during chronic 
progressive HIV disease, HIV-specific CD8 T-cells lose their ability to proliferate, 
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become non-cytolytic and lose polyfunctionality (Peretz et al., 2012; Trautmann et al., 
2006; Yamamoto et al., 2011). 
Several studies have shown a strong association between high levels of the 
inhibitory receptor PD-1, viral loads and disease progression (D'Souza et al., 2007; Day 
et al., 2006; Freeman, Wherry, Ahmed, & Sharpe, 2006; Petrovas et al., 2006; Trautmann 
et al., 2006; Yamamoto et al., 2011).  A previous study found that CD8 T-cells from elite 
controllers expressed remarkably low levels of PD-1 compared to that of chronic 
progressors (Zhang et al., 2007).   
However, T cell exhaustion is characterized by an accumulation of inhibitory 
receptors including CD160 and 2B4 (Blackburn et al., 2008; Peretz et al., 2012; 
Yamamoto et al., 2011).  To better understand the relationship between expression of 
inhibitory receptors and T-cell function in the context of elite control of HIV infection, 
we measured PD-1, Lag-3, CD160 and 2B4 expression patterns on HIV-specific CD8 T-
cells from elite controllers and chronic progressors.  In addition, we assessed the ability 
of CD8 T-cells expressing multiple inhibitory receptors to produce effector functions 
such as IFNγ, TNF and perforin.  We found that Gag-specific CD8 T-cells from elite 
controllers co-express PD-1, CD160 and 2B4 suggesting a level of exhaustion similar to 
that of chronic progressors.  However, elite controllers also have a large population of 
Gag-specific CD8 T-cells co-expressing CD160 and 2B4 that is associated with cytolytic 
potential.  Together these data suggests that the co-expression of inhibitory markers on 
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HIV-specific CD8 T-cells must be interpreted within the context of T-cell function and 
phenotype, as well as HIV disease control status. 
 
MATERIALS AND METHODS 
PBMC samples: See chapter 2. 
Antibodies 
Antibodies for surface staining included anti-CD4 PE-Cy5.5 (clone S3.5, Invitrogen), 
anti-CD8 Qdot605 (clone 3B5, Invitrogen) or Brilliant Violet 605 (clone RPA-T8, 
Biolegend), anti-CD27 Qdot 655 (clone CLB-27/1, Invitrogen) or Brilliant Violet 650 
(clone O323, Biolegend), anti-CD45RO ECD (clone UCHL1, Beckman Coulter), anti-
PD-1 PE (clone EH12.2 H7, Biolegend), anti-CD160 (Cai et al., 2008), conjugated in-
house) FITC and anti-CD244 (2B4) PE-Cy5 (clone C1.7, Beckman Coulter), anti-CD14 
APC-AF750 (clone TüK4, Invitrogen), anti-CD19 APC-AF750 (clone SJ25-C1, 
Invitrogen), anti-Lag-3 biotin (polyclonal, R&D Systems), Streptavidin-APC 
(Invitrogen), and anti-APC biotin (clone eBioAPC-62A, eBiosicience).  Antibodies for 
intracellular staining included anti-CD3 Qdot 585 (custom conjugation performed in our 
laboratory as previously described (Chattopadhyay et al., 2006) or Brilliant Violet 570 
(clone UCHL1, Biolegend), anti-Perforin Pac Blue (clone B-D48, custom conjugation 
performed in our laboratory as previously described (Chattopadhyay et al., 2006) or 
Brilliant Violet 421 (clone B-D48, Biolegend), anti-IFN-γ Alexa-700 (clone B27, 
Invitrogen), and anti-TNF PE-Cy7 (clone MAb11, BD Biosciences).  
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PBMC Stimulation 
 Cryopreserved PBMCs were thawed and then rested overnight at 37°C, 5% CO2 
in complete medium [RPMI (Mediatech Inc; Manassas, Virginia) supplemented with 
10% FBS, 1% L-glutamine (Mediatech Inc; Manassas, Virginia) and 1% Penicillin-
streptomycin (Lonza; Walkersville, Maryland), sterile filtered at a concentration of 2x106 
cells/ml of medium.  The next day, the cells were washed with complete medium and 
resuspended at a concentration of 1x106 cells/ml with co-stimulatory antibodies (anti-
CD28 and anti-CD49d; 1µg/ml final concentration; BD Biosciences; San Jose, 
California), in the presence of brefeldin A (1µg/ml final concentration; Sigma-Aldrich; 
St. Louis, Missouri).  Next, cells were stimulated with exogenous peptide pools for HIV 
gag-PTE (NIH AIDS Reference Reagent Program) or EBV proteins (BCRF1, BMLF1, 
BMRF1, BRLF1, BZLF1, gp85, gp110, gp350 and EBNA4 at 2µg/mL each peptide) at 
5µL/mL.  Stimulation with SEB (1 µg/ml; Sigma-Aldrich) was used as a positive control 
or DMSO (5µL/mL) as a negative control.  PBMCs were then incubated at 37°C, 5% 
CO2 for 5 hours.  
FACS staining assay: See chapter 2. 
Flow cytometry analysis: See chapter 2. 
 
RESULTS 
Expression of PD-1, Lag-3, CD160 and 2B4 on HIV- & EBV-specific CD8 T-cells 
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 To investigate the potential level of T-cell exhaustion within HIV elite controllers, 
we measured expression of PD-1, Lag-3, CD160 and 2B4 on HIV-specific CD8 T-cells. 
For comparison, we also measured expression of these inhibitory receptors on EBV-
specific CD8 T-cells known to express high levels of PD-1 but remain functional 
(Petrovas et al., 2006). Virus-specific CD8 T-cells were identified by intracellular 
staining for IFNγ and TNF after 6 hours of stimulation with an overlapping peptide pool 
spanning the HIV Gag protein or with an EBV peptide pool containing previously 
defined EBV epitopes derived from the EBV proteins BCRF1, BMLF1, BMRF1, 
BRLF1, BZLF1, gp85, gp110, gp350 and EBNA4 for CD8 T-cell responses.  Figures 6A 
and B show representative flow cytometry plots of PD-1, Lag-3, CD160 and 2B4 
expression on HIV and EBV-specific cells from EC and CP, as well as EBV-specific 
CD8 T-cells from HIV- subjects overlaid onto corresponding memory populations.   
Similar to the memory compartment, HIV-specific CD8 T-cells from EC 
expressed less PD-1 (mean: 50%) and more CD160 (mean: 65%) than CP (mean: 75%, 
p<0.0001; mean: 20%, p<0.0001 respectively) (Figure 6C).  Gag-specific CD8 T-cells 
from EC and CP had a higher proportion of PD-1 expression compared to their memory 
subset (p=0.0004, p<0.0001 respectively) but not CD160 or 2B4 (Figure 7A and B).  
Gag-specific CD8 T-cells from EC also had a higher proportion of Lag-3 expression 
compared to the memory population (p=0.006).  In comparison, EBV-specific CD8 T-
cells from EC and CP had similar levels of PD-1, Lag-3 and 2B4 expression; but 
CD160+ EBV-specific cells were significantly higher in EC (mean: 60%) compared to 
CP (mean: 20%, p <0.001; Figure 6D).  Unlike HIV-specific CD8 T-cells, the proportion 
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of PD-1, Lag-3 and CD160 expression on EBV-specific CD8 T-cells from EC and CP did 
not significantly differ from that of their corresponding memory populations; however, a 
higher proportion of EBV-specific CD8 T-cells from HIV- individuals expressed PD-1 
and Lag-3, but less CD160, than their memory populations (p=0.04, p=0.003, p=0.03 
respectively)  (Figure 7C).   
 
Gag-specific CD8 T-cells from EC express multiple inhibitory receptors 
We next evaluated co-expression of PD-1, Lag-3, CD160 and 2B4 on HIV and 
EBV-specific CD8 T-cells.  HIV-specific CD8 T-cells from EC were mainly distributed 
between three major populations: PD-1+CD160+2B4+, CD160+2B4+ and PD-1+2B4+ 
with a small percentage of cells expressing only 2B4 (Figure 8A).  In comparison, HIV-
specific CD8 T-cells from CP were restricted into two major populations: PD-
1+CD160+2B4+ and at a higher proportion than EC, PD-1+2B4+ (p<0.0001), with a 
minor proportion expressing 2B4 alone (Figure 8A).  Consistently, EBV-specific CD8 T-
cells from EC, CP and HIV- subjects expressed the same key combinations of inhibitory 
receptors seen in HIV-specific cells (Figure 8B).   
Previous work has linked the co-expression of 3 or more inhibitory receptors on 
antigen-specific CD8 T-cells to exhaustion (Bengsch et al., 2010; Blackburn et al., 2008; 
Riches et al., 2013; Yamamoto et al., 2011); therefore, we examined the number of 
receptors co-expressed by HIV and EBV-specific CD8 T-cells.  Thirty percent of HIV-
specific CD8 T-cells from EC expressed any combination of 3 inhibitory receptors.  
Surprisingly, a significantly smaller proportion of the HIV-specific CD8 T-cells from CP 
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expressed 3 inhibitory receptors (19%, p<0.01) (Figure 9A).  Of interest, a considerable 
percentage of HIV-specific CD8 T-cells from EC (46%) and CP (52%) expressed only 2 
inhibitory receptors (Figure 9A), indicating that a large portion of the HIV-specific CD8 
T-cell response falls within this group.  On the other hand, EBV-specific CD8 T-cells 
from EC, CP and HIV- subjects are equably divided between co-expression of 2 
inhibitory receptors and a single inhibitory receptor (Figure 9B). Together, this data 
suggests that even though previous work has associated the triple positive (TP) 
population PD-1+CD160+2B4+ with T-cell exhaustion, the presence of this population 
alone does not explain the differences between EC and CP; instead, the presence or 
absence of the CD160+2B4+ and PD1+2B4+ populations could contribute to the 
differences between EC and CP. 
 
Co-expression of CD160 and 2B4 is associated with cytolytic capacity of CD8 T-cells 
Highly functional effector HIV-specific CD8 T-cells are preferentially maintained 
and are an important component in the control of HIV replication (Almeida et al., 2007; 
Betts et al., 2006; Hersperger et al., 2010).  Effector responses can be characterized by 
the presence of the cytolytic molecule perforin, along with expression of IFNγ and/or 
TNF and the lack of IL-2 expression (Makedonas et al., 2010).  In addition, expression of 
PD-1 has been associated with decreased cytolytic effector function, but CD160 and 2B4 
have been shown to both stimulate and inhibit cytolytic activity (Meinke & Watzl, 2013; 
Nikolova et al., 2002; 2005; Rey et al., 2006; Schlaphoff et al., 2011; Sinha, Gao, Guo, & 
Yuan, 2010; Šedý et al., 2013; Viganò et al., 2014; Yamamoto et al., 2011). Furthermore, 
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there is evidence that expression of these markers increases upon activation and those 
cells remain functional (Legat et al., 2013; Meinke & Watzl, 2013; Nikolova et al., 2005; 
Zelinskyy et al., 2011).  
To examine the relationship between expression of PD-1, CD160 and 2B4 in the 
context of CD8 T-cell functionality, we first assessed the functional profile of the HIV-
specific and EBV-specific CD8 T-cells by staining for the cytolytic marker perforin in 
combination with IFNγ and TNF.  Representative flow cytometry plots indicating the 
gating scheme is shown in figure 10A. In accordance to previous reports, EC had a higher 
proportion of perforin+ HIV-specific responses (p<0.01) compared to CP, whose 
responses consisted mainly of IFNγ+ CD8 T-cells (p<0.001) (Figure 10B).  Similarly, EC 
had a high proportion of perforin+ EBV-specific responses compared to CP and HIV-
negative individuals (p<0.5), but a large proportion of the EBV-specific response from 
the tree groups was TNF+IFNγ+ (Figure 10).  Next, we divided responding cells into two 
subsets; effector responses: perforin+ (IFNγ+ and/or TNF+) and memory responses: 
perforin- (IFNγ+ and/or TNF+), and assessed the co-expression of PD-1, CD160 and 2B4 
(Figure 11).  
A significantly high proportion of the perforin+ HIV and EBV-specific responses 
were grouped within the PD-1 negative subsets.  In contrast, a significant portion of the 
perforin- (IFNg+ and/or TNF+) HIV and EBV-specific responses were grouped within 
the PD-1+ subsets (Figure 11A and B). We next assessed the relationship between 
perforin and PD-1, CD160 and 2B4 expression individually or in combination by HIV-
specific CD8 T-cells. We found an inverse correlation between perforin and PD-1 (Figure 
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12A), but not with CD160 or 2B4 (Figure 12B and C). However, there was a negative 
correlation between the fraction of perforin+ effector responses and the proportion of 
responding cells co-expressing PD-1+2B4+, and a positive correlation with co-expression 
of CD160+2B4+ in both HIV and EBV-specific CD8 T-cells (Figure 13A and B).  
Together these data suggest that specific inhibitory receptor co-expression patterns define 
CD8 T-cells with different functional capacities and that certain inhibitory receptor 
combinations may be associated with markers of viral control.  
 
DISCUSSION 
We have previously shown that perforin expression by HIV-specific CD8 T-cells 
is a correlate of protection against HIV disease progression in HIV elite controllers 
(Hersperger et al., 2010).  Interestingly, our results indicate that perforin expression in 
HIV-specific CD8 T-cells in EC and CP is highly associated with the expression of 
CD160 and 2B4.  These two co-receptors have been shown to have both inhibitory and 
stimulatory roles in effector functions of T-cells and NK cells. (Meinke & Watzl, 2013; 
Merino et al., 2007; Nikolova et al., 2002; 2005; Rey et al., 2006; Schlaphoff et al., 2011; 
Sinha et al., 2010; Šedý et al., 2013; Viganò et al., 2014; Yamamoto et al., 2011).  CD160 
can be expressed in two isotypes: GPI-anchored (CD160-GPI) and with a transmembrane 
domain (CD160-TM).  Cross-linking CD160-GPI has been shown to have an activating 
effect on CD4 and CD8 T-cell function (El-Far et al., 2014).  However the signaling 
pathway of CD160-TM has not been characterized, and further studies are necessary to 
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elucidate a possible role in T-cell exhaustion.  On the other hand, the duality of 2B4 has 
been associated to expression levels of the adaptor proteins SAP and EAT-2 or 
recruitment of FynT (Meinke & Watzl, 2013).  Our results imply that expression of 
CD160 and 2B4, rather than signifying exhaustion, may identify a population of activated 
cytolytic CD8 T-cells important in the response against HIV.   In this context, CD160 and 
2B4 may be acting as activating co-receptors and not as inhibitory receptors. We 
therefore hypothesize that PD-1 signaling in the exhausted triple positive population 
tempers the association between perforin, CD160 and 2B4.  Further studies are necessary 
to elucidate if a downstream target of PD-1 signaling modulates CD160-TM signaling as 
well as its involvement in modulating 2B4 downstream signaling by regulating SAP or 
FynT levels.  
Differences between elite controllers and chronic progressors have been studied in 
order to identify correlates of protection that can be used to improve current therapies and 
develop vaccines against HIV.  Efforts to revitalize antigen-specific CD8 T-cell 
responses to chronic infections and cancer by blocking the PD-1 inhibitory pathway are 
ongoing and clinical trials in solid tumors show promising results (reviewed in (Harvey, 
2014); A5326: Anti-PD-L1 Antibody in HIV-1, https://actgnetwork.org/study/a5326-anti-
pd-l1-antibody-hiv-1; NCT01629758: Safety Study of IL-21/Anti-PD-1 Combination in 
the Treatment of Solid Tumors, 
http://www.clinicaltrials.gov/ct2/show/NCT01629758?term=PD-1&rank=4).  This study 
shows that not all “inhibitory” receptors are detrimental and in fact some may play a 
positive role in the anti-viral response.  In the context of HIV infection, studies involving 
46 
 
expression of inhibitory receptors and T-cell exhaustion would benefit from 
simultaneously measuring effector functions such as proliferation, IL-2 and perforin 
production, since these functions delineate different but important T-cell populations and 
are not always expressed by the same cell.  Additionally, expression of inhibitory 
receptors is not only linked to T-cell exhaustion but also to differentiation/activation 
status, antigen specificity and anatomical localization (Baitsch et al., 2012; Legat et al., 
2013).  For the development of new therapeutics, one must take into account the context 
in which inhibitory markers are being expressed and whether expression signifies 
exhaustion or delineates an immunologically important population.   Additionally, it is 
important to understand the unintended consequences blocking these inhibitory receptor 
pathways may have on non-exhausted T-cell populations.   
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Figure 6: PD-1, Lag-3, CD160 and 2B4 expression on HIV and EBV-specific CD8 T-
cells. 
PBMCs were stimulated for 6 hours with a Gag-PTE peptide pool or an EBV pool 
containing peptides derived from lytic proteins.  Responding CD8 T-cells were identified 
by IFNγ and TNF production. (A) Representative flow cytometry plots of PD-1, Lag-3, 
CD160 and 2B4 expression on HIV-specific (red) and (B) EBV-specific (blue) CD8 T-
cells. (C) Percentage of Gag-specific CD8 T-cells expressing individual inhibitory 
receptors. (D) Percent of EBV-specific CD8 T-cells expressing individual inhibitory 
receptors. Error bars represent mean + SEM. ** p<0.01, *** p<0.001 
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Figure 7: Comparison between the proportion of memory, HIV and EBV-specific 
CD8 T-cells  
The proportion of memory CD8 T-cells expressing individual inhibitory receptors was 
compared to the proportion of expression on HIV-specific and EBV-specific CD8 T-
cells. (A) elite controllers (EC), (B) Chronic progressors (CP), (C) HIV-negative. Bars 
represent the mean and error bars indicate SEM. *p<0.05, ** p<0.01, *** p<0.001 
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Figure 9: Number of inhibitory receptors expressed by HIV and EBV-specific CD8 
T-cells. 
(A) Percent of Gag-specific CD8 T-cells co-expressing inhibitory receptors. (B) Percent 
of EBV-specific CD8 T-cells co-expressing inhibitory receptors. HIV-negative (blue 
line), CP (red line), and EC (green line). Error bars represent mean + SEM. * p<0.05, ** 
p<0.01, *** p<0.001 
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Figure 10: Functional profile of HIV and EBV-specific CD8 T-cells.  
Proportion of cytokine and perforin production by CD8 T-cells in response to peptide 
pool stimulation of PBMCs with a Gag-PTE peptide pool or an EBV pool containing 
peptides derived from lytic proteins. (A) Representative flow cytometry plots showing 
the gating scheme for IFNγ, TNF and perforin expression. (B) HIV Gag-specific 
response. (C) EBV-specific response. HIV-negative (HIV-, blue bars), chronic 
progressors (CP, red bars) and elite controllers (EC, green bars). Bars represent mean of 
expression: each dot represents a subject.  
* p<0.05, ** p<0.01, *** p<0.001 
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Figure 11: PD-1, CD160 and 2B4 co-expression on perforin+ and perforin virus-
specific CD8 T-cells.  
Responding CD8 T-cells identified by IFNγ and/or TNF production were divided into 
perforin+ and perforin- responses. (A) Relative expression of each possible inhibitory 
receptor expression profile of perforin+ (dark gray) and perforin- (light gray) HIV-specific 
responses from EC (top) and CP (bottom). (B) Relative expression of each possible 
inhibitory receptor expression profile of perforin+ (dark gray) and perforin- (light gray) 
EBV-specific responses from HIV negative (top), EC (middle) and CP (bottom). Bars 
represent mean of expression: each dot represents a subject.  
** p<0.01  
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Figure 12. Association between perforin and expression of PD-1 but not CD160 or 
2B4. 
Correlation between the percent of the HIV-specific CD8 T-cell response that is perforin+ 
and the percent of the response expressing (A) PD-1, (B) CD160 or (C) 2B4. CP (red 
dots), EC (green dots).  Spearman R and p value of correlations are depicted in the upper 
right corner of each graph.  Lines represent linear regression.  
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Figure 13. Association between perforin and co-expression of CD160 and 2B4. 
Correlation between the percent of the (A) HIV-specific and (B) EBV-specific CD8 T-
cell response that is perforin+ and the percent of the response co-expressing inhibitory 
receptors. HIV negative (blue dots), CP (red dots), EC (green dots).  Spearman R and p 
value of correlations are depicted in the upper right corner of each graph.  Lines represent 
linear regression.  
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CHAPTER 4: EXPRESSION OF INHIBITORY RECEPTORS IN HIV+ LYMPH 
NODES IN CHRONIC PROGRESSORS AND SUBJECTS ON 
ANTIRETROVIRAL THERAPY 
SUMMARY 
 Early in HIV infection viral replication occurs preferentially in tissues, including 
the gastrointestinal tract and secondary lymphoid organs (Pantaleo et al., 1991). Viral 
replication in LNs exceeds the levels in plasma by several orders of magnitude and is 
associated with a gradual destruction of the highly ordered architecture of the LN, 
marked by a follicular hyperplasia, massive CD4 T-cell apoptosis, and the final 
involution of the LN (Cohen, Pantaleo, Lam, & Fauci, 1997).   
ELISpot assays were used to detect HIV-specific responses in lymph nodes even 
after full viral suppression on ART (Altfeld et al., 2002).  These observations suggested 
that lymph nodes are also major sites of viral replication and harbor the viral reservoir 
even when virus is undetectable in blood (Altfeld et al., 2002).  Though immune 
responses to HIV infection have been widely studied in blood, much less is known about 
the role of the virus-specific cellular immune responses in the lymphoid tissues.  To this 
day, HIV remains an incurable disease, partly due to the inability to find and eliminate 
latently infected CD4 T cells.  Cytolytic CD8 T cells resident in the lymph nodes are 
good candidates for that task.  Here, we measured markers of exhaustion on CD8 T cells 
from HIV chronic individuals (CP) and HIV+ individuals on antiretroviral therapy (ART) 
and compared it to expression on CD8 T cells from blood.  We find that CP lymph nodes 
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have a large proportion of exhausted PD-1+CD160+2B4+ HIV-specific CD8 T cell 
population than that in blood. We also found that LN CD8 T cells express low levels of 
T-bet, a transcriptor factor associated with perforin expression. However we also find that 
in LN, perforin expression dissociates from T-bet, suggesting there are other factors 
involved in modulating cytolytic activity within these tissues.    
 
INTRODUCTION 
Lymphatic tissues contain 95% of the body’s lymphocytes, with approximately 
41% residing in lymph nodes, 15% in the spleen and 20% in gut tissues including GALT 
and LP. In contrast, only 2% of total lymphocytes are found in the blood (Ganusov & De 
Boer, 2007). Lymph nodes are of great immunological significance in the fight against 
infection and are major sites of antigen presentation and surveillance (Altfeld et al., 
2002).  Lymph contain 95% of the body’s lymphocytes and are major site of antigen 
presentation and surveillance (Altfeld et al., 2002).  The lymph node structure separates T 
cells into the T-cell zone and B cells into the B cell follicle.  When dendritic cells from 
tissues migrate to lymph nodes carrying antigens they stimulate naive T cells by 
interactions between the T cell receptors and MHC-I:antigen complexes and other co-
stimulatory molecules.  Activated CD4 T-cells (TFH) then migrate into B cell follicles and 
form germinal centers, where they stimulate B cell proliferation, antibody production and 
isotype switching.  Follicular dendritic cells (FDC) bind antigen-antibody complexes in 
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germinal centers and serve to stimulate T-cells in the T-cell zone and drive affinity 
maturation of the B cell response (reviewed in (Mondino, Khoruts, & Jenkins, 1996).  
 During the initial stages of HIV infection dendritic cells and macrophages present 
in GALT are among the first to encounter the virus.  HIV then uses these cells as vehicles 
to reach the lymph nodes where it gains access to a target rich environment (Baxter et al., 
2014; Harman, Kim, Nasr, Sandgren, & Cameron, 2013; Nasr et al., 2014).  In fact, a 
large number of latently infected CD4 T-cells and macrophages can be found in LN 
through out the course of disease (Embretson et al., 1993).  Though NK cells in the 
periphery respond to HIV infection and are able to kill infected cells (O'Connell et al., 
2009), these cytotoxic NK cells do not accumulate in LN during acute infection (Luteijn 
et al., 2011), allowing robust viral replication and viral reservoirs to be established 
(Pantaleo et al., 1991).   
Current antiretroviral therapies reduce viral replication to undetectable levels in 
both blood and lymph nodes, but that requires strict adherence to treatment guidelines 
(Gray et al., 2000). However, treatment interruption and lapses in adherence allow HIV 
viral loads rebound (Altfeld et al., 2002) and can allow new T cell depletion and drug 
resistant mutations that result in therapy failure.  Immune reconstitution during 
antiretroviral therapy (ART) has been shown to be incomplete regardless of increased 
CD4 and CD8 T-cell numbers, particularly affecting GALT (MD et al., 2009).  
Furthermore, with new infections in adolescents and young adults on the rise, the number 
of years an individual will spend on ART has increased significantly.  This brings into 
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question the long-term effects of ART.  Thus there is a vast effort to find a viable way of 
eradicating the viral reservoir present in lymphatic tissues and de-intensify the use of 
antiretroviral drugs.    
There are Important differences between blood and lymph node CD8 T-cells 
during HIV infection, including significantly lower levels of perforin expression in LN 
(O. O. Yang et al., 2005). Furthermore, Immunohistochemistry studies showed high 
levels of PD1 expression mostly on CD45R0+ helper/inducer T-cells (TFH) localized in 
the germinal centers, these levels do not change after initiation of ART (Cubas et al., 
2013; MD et al., 2009).  PD-1 is expressed on a small proportion of LN CD8 T-cells on 
chronic subjects, after ART the levels of expression on CD8 T cells remained the same, 
the number of PD-1+ CD8 T cells within the LN was significantly reduced (MD et al., 
2009). T cell exhaustion in the context of HIV infection has been mainly characterized 
using T-cells derived from blood.  Tissue specific differences in PD-1 expression in 
animal models (Blackburn et al., 2010) and humans (Fourcade et al., 2012; Kroy et al., 
2014; MD et al., 2009; Wu et al., 2014) highlight the importance of understanding T cell 
exhaustion in tissues relevant to disease. In the case of HIV infection, lymph nodes are a 
major source of target cells, viral replication and harbor the viral reservoir. 
Efforts to reinvigorate the immune system, primarily by blocking interactions 
between PD-1 and PD-L1, have shown that the PD-1 profile of PBMCs is not sufficient 
to predict how an individual will react to PD-1 blockade therapy. In the context of HCV 
infection, CD8 T cells in the liver were highly PD-1 positive, profoundly dysfunctional, 
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and poorly responsive to PD-1/PD-L blockade, unlike CD8 T cells in blood. This suggest 
a differential level of HCV-specific CD8 T-cell exhaustion in HCV-infected patients that 
is defined by their compartmentalization and PD-1 expression (Nakamoto et al., 2008).  
This data also emphasizes that looking at the PD-1 expression profile in lymph nodes is 
crucial to understanding the effects on blockade therapy and if the CD8 T-cells present in 
LN will be able to eliminate the HIV reservoir.  
The ability of CD8 T cells to directly kill target cells is associated with expression 
of the lytic molecule perforin. However, the proportion of CD8 T cells in the lymph node 
that express perforin is small (O. O. Yang et al., 2005).  Whether the low level of perforin 
expression is low due to tissue-specific requirements or due to exhaustion remains to be 
determined.  Here, we measure transcription factor T-bet, a member of the T-box family, 
is involved in T-cell development and modulation of effector functions.  T-bet expression 
reached its maximal induction at the effector phase and partially declined in the memory 
phase (Takemoto, Intlekofer, Northrup, Wherry, & Reiner, 2006).  Expression of high 
levels of T-bet correlates with effector CD8 T cell phenotype in blood and it is associated 
with cytolytic activity in elite control of HIV (Buggert et al., 2014; Hersperger et al., 
2011; Kao et al., 2011; Knox, Cosma, Betts, & McLane, 2014). Our previous study 
(chapter 3) showed an association between CD160+2B4+ expression and perforin.   
Therefore we assessed if there is an association between co-expression of these receptors 
and expression of the transcription factor T-bet in blood and lymph nodes.  
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MATERIALS AND METHODS 
PBMC and LNMC samples 
Peripheral blood mononuclear cells (PBMC) were obtained from HIV negative 
subjects at the University of Pennsylvania's Center for AIDS Research Immunology Core 
and cryopreserved in fetal bovine serum (FBS; ICS Hyclone, Logan Utah) containing 
10% dimethyl sulfoxide (DMSO; Fisher Scientific, Pittsburgh, Pennsylvania). Lymph 
node mononuclear cells (LNMC) from HIV negative individuals were obtained from the 
Geriatric Research, Education and Clinical Center (GRECC), Louis Stokes Cleveland VA 
Medical Center, Division of Infectious Disease, Case Western Reserve University.   
PBMCs and LNMCs from HIV positive individuals were obtained from the Center for 
Research on Infectious Disease (CIENI), National Institute of Respiratory Disease, 
Mexico DF, Mexico. All samples were collected in compliance with the guidelines set by 
the institutional IRBs. 
Chronic progressors (CP) were defined as untreated individuals with HIV plasma 
RNA levels >4,000 copies/mL (range: 4,000-150,00, mean: 66,000), diagnosed for >1 
year and ART naïve. ART subjects were defined as on therapy for >6 months and fully 
suppressed viral loads <100 HIV RNA copies/mL. All subjects had CD4 counts >200 
cells/mm3.  
Antibodies 
Antibodies for surface staining included anti-CD4 PE-Cy5.5 (clone S3.5, 
Invitrogen), anti-CD8 BV605 (clone RPA-T8, Biolegend), anti-CD27 BV650 (clone 
O323, Biolegend), anti-CD45RO ECD (clone UCHL1, Beckman Coulter), anti-PD-1 
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BV711 (clone EH12.2 H7, Biolegend), anti-CD160 FITC ((Cai et al., 2008)), anti-CD244 
(2B4) PE-Cy5 (clone C1.7, Beckman Coulter), anti-CD14 APC-Cy7 (clone TüK4, 
Invitrogen), anti-CD19 APC-Cy7 (clone SJ25-C1, Invitrogen). Antibodies for 
intracellular staining included anti-CD3 BV570 (clone UCHL1, Biolegend), anti-T-bet 
PE (clone 4B10, eBioscience), anti-Perforin BV421 (clone B-D48, Biolegend), anti-IFN-
γ Alexa-700 (clone B27, Invitrogen), and anti-TNF PE-Cy7 (clone MAb11, BD 
Biosciences). 
 
PBMC and LNMC Stimulation 
 Cryopreserved PBMC and LNMC were thawed and rested overnight at 37°C, 5% 
CO2 in complete medium [RPMI (Mediatech Inc; Manassas, Virginia) supplemented with 
10% FBS, 1% L-glutamine (Mediatech Inc; Manassas, Virginia) and 1% Penicillin-
streptomycin (Lonza; Walkersville, Maryland) at a concentration of 2x106 cells/ml of 
medium. The cells were then washed with complete medium and re-suspended at a 
concentration of 1x106 cells/ml with co-stimulatory antibodies (anti-CD28 and anti-
CD49d; 1µg/ml final concentration; BD Biosciences; San Jose, California), in the 
presence of brefeldin A (1µg/ml final concentration; Sigma-Aldrich; St. Louis, Missouri). 
Next, cells were stimulated with exogenous peptide pools for HIV Gag-PTE (NIH AIDS 
Reference Reagent Program) or EBV proteins (BCRF1, BMLF1, BMRF1, BRLF1, 
BZLF1, gp85, gp110, gp350 and EBNA4) at 400µg/ml. Stimulation with SEB (1 µg/ml; 
Sigma-Aldrich) was used as a positive control or DMSO (5µL/mL) as a negative control. 
PBMC and LNMC were stimulated at 37°C, 5% CO2 for 5 hours. 
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FACS staining assay 
 After stimulation, cells were washed once with FACS buffer and stained with 
Aqua amine-reactive viability dye (Invitrogen) for 10 minutes to exclude non-viable 
events, the cells were then stained for surface markers with an antibody cocktail for an 
additional 30 minutes. Following a wash with FACS buffer, cells were permeabilized 
with Cytofix Cytoperm (BD Biosciences) as per manufacturer’s instructions. Next, a 
cocktail of antibodies against intracellular markers was added and incubated for an hour.  
Lastly, cells were washed with Perm Wash Buffer (BD Biosciences) and fixed in PBS 
containing 1% paraformaldehyde. All incubations were done at room temperature in the 
dark.  Fixed cells were stored at 4°C until the time of collection. 
Flow cytometric analysis 
 For each sample, between 5x105 and 1x106 total events were acquired on a 
modified flow cytometer (LSRII; BD Immunocytometry systems) equipped for the 
detection of 18 fluorescent parameters and longitudinally standardized for signal 
consistency using the previously described calibration methods (Perfetto et al., 2012). 
Antibody capture beads (BD Biosciences) were used to prepare individual fluorophore 
matched compensation tubes for each antibody used in the experiments. Data analysis 
was performed using FlowJo version 9.8.1 (TreeStar, Inc). Reported functional data have 
been corrected for background.  Statistical analysis was performed with Prism version 
5.0. Comparisons between HIV negative blood and LN samples were analyzed using the 
Mann-Whitney tests.   Comparisons between HIV blood and LN samples from CP and 
ART treated individuals were analyzed using a paired T test since this samples were 
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matched.  Comparisons amongst cohort groups were analyzed using one-way ANOVA 
tests (nonparametric; Kruskal-Wallis) followed by a Dunns test for multiple comparisons.  
Correlation coefficients were calculated using the Spearman rank sum test.  All tests were 
2-tailed and P values less than 0.05 were considered significant.  
 
RESULTS 
High expression of PD-1 by CD8 T cells from lymph nodes compared to blood  
To determine if the levels of T-cell exhaustion, in blood are representative of the 
lymph node environment and determine the effect of antiretroviral therapy, we collected 
matched CD8 T-cells from blood (PBMCs) and lymph nodes (LNMCs) from 14 HIIV 
chronic progressors (CP), 9 HIV+ patients on ART (ART) and 15 (not matched) HIV 
negative individuals.  We used polychromatic flow cytometry to simultaneously measure 
expression of inhibitory receptors PD-1, CD160 and 2B4 as a measure of exhaustion.  
Blood and lymph node samples were analyzed together to minimize experimental 
variability.  Representative flow cytometry plots showing the gating scheme for analysis 
of PD-1, CD160 and 2B4 are shown in figure 14.  Differential expression of CD27 and 
CD45RO was used to identify naïve CD8 T cells (Figure 14A). As with the previous 
study (Chapter 2), the naïve population from PBMCs was used as reference to determine 
surface expression of individual inhibitory receptors. Gates from the PBMC sample was 
then “dropped” onto the corresponding LNMCs.  Flow cytometry plots showing 
differential expression of PD-1, CD160 and 2B4 on naïve and memory CD8 T cells from 
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blood and lymph node from a CP, ART and an HIV negative subject are shown in Figure 
14B and C.   
 The presence of a larger proportion of naïve CD8 T-cells in the lymph nodes 
compared to blood (Figure 15A) can skew comparisons between these two 
compartments; therefore we excluded this population from further analysis.  Additionally, 
HIV negative subjects have more naïve CD8 T-cells compared to both CP and ART 
subjects (Figure 15A).  Lymph nodes also have a larger proportion of CM, no significant 
difference between HIV negative, CP and ART subjects (Figure 15B).  There is a greater 
proportion of EM CD8 T-cells in HIV positive subjects compared to HIV negatives. 
(Figure 15C). Of note, there is also a large difference in the proportion of effector cells 
found in blood versus the lymph node (Figure 15D).   
In the blood, CP shows a trend towards higher expression of PD-1 compared to 
ART or HIV negative subjects though it does not reach statistical significance (Figure 
16A).  However, expression of CD160 and 2B4 is significantly higher in CP compared to 
HIV negative subjects (p<0.001) (Figure 16A).  Of note, expression of CD160 in chronic 
progressors is higher in this cohort than CP from the cohort used in our previous study 
(Figure 4).  A caveat of this study is that we are comparing CP and ART subjects from 
Mexico City to HIV negative subjects from the United States.  Genetic or environmental 
differences could explain the discrepancy in CD160 expression.  This issue can be 
addressed by sampling HIV negative subjects in the same geographical area as a control.   
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In the lymph node, chronic progressors expressed significantly more PD-1 than 
HIV negative subjects (p<0.001) and there is reduced expression on ART subjects 
(Figure 16B).  Expression of CD160 in LN was not statistically different between the 
three groups.  2B4 expression was higher in CP than HIV negative subjects (p<0.001).  
Subjects on ART showed a trend towards lower expression than CP (Figure 16B).  
Overall, the relationships of inhibitory receptor expression observed in blood are 
preserved in the LN. 
Next, we compared expression individual of inhibitory receptors on memory CD8 
T cells from blood to those from LN.  PD-1 expression is significantly higher in LN 
memory CD8 T cells compared to blood in CP (p<0.001), ART (p<0.01) and HIV 
negative subjects (p<0.5) (Figure 17A).  CP and ART subjects also have a significantly 
higher per-cell expression (MFI) of PD-1 in LN compared to blood (p<0.001, p<0.01 
respectively) (Figure 17B).  Though there are no differences in the proportion of CD160+ 
memory CD8 T cells in LN or blood, the per-cell levels of expression in HIV negative 
LN is significantly higher than that of blood (p<0.01) (Figure 17C and D).  Interestingly, 
both the proportion and per-cell levels of 2B4 expression in blood and LN from CP and 
ART subjects did not differ, but the proportion in HIV negative lymph nodes was 
significantly lower (p<0.01) (Figure 17E and F).     
Co-expression of CD160 and 2B4 by CD8 T cells from Chronic progressors and HIV+ 
on ART  
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 To assess any differences in the level of CD8 T-cell exhaustion in lymph nodes 
and blood, we measured the co-expression of PD-1, CD160 and 2B4.  Various groups 
have shown that co-expression of these receptors define a population of exhausted CD8 
T-cells in blood (Figure 18).  In agreement with our previous findings, memories CD8 T-
cells from blood of HIV negative individuals were primarily PD-1-CD160-2B4+ and to a 
smaller proportion PD-1-CD160+2B4+. In comparison, LN memory CD8 T-cells had a 
range of co-expression and did not associate with any one co-expression pattern (Figure 
18, top graph).  On the other hand, a large portion of the blood and LN memory CD8 T-
cells from CP and ART subjects were primarily grouped into PD-1+CD160+2B4+, PD-1-
CD160+2B4+, with a greater proportion of blood memory CD8 T cells in this category, 
and to a lower extent PD-1-CD160-2B4+ (Figure 18, middle and bottom graphs). Of note, 
there is a significant proportion of PD-1-CD160+2B4+ in CP and ART, a population we 
associated with perforin expression in the previous cohort (Figure 13).  
Expression of PD-1, CD160 and 2B4 on HIV and EBV-specific CD8 T cells in blood and 
lymph node 
 To further investigate differences in expression of PD-1, CD160 and 2B4 on CD8 
T-cells from blood and lymph node, and to assess the extent of HIV-specific exhaustion, 
we measured expression of these inhibitory receptors on Gag-specific and EBV-specific 
CD8 T-cells by flow cytometry.  Simultaneously we measured production of IFNγ, TNF 
and perforin.  Representative flow cytometry plots showing the gating strategy to identify 
responding cells are shown in figure 19. Perforin+ cells were considered responding cells 
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when express with IFNγ and/or TNF.  Boolean gates were then used to assess the 
polyfunctionality of CD8 T-cells responding to HIV-Gag or EBV.  In accordance to 
previous reports (O. O. Yang et al., 2005), HIV-Gag and EBV-specific CD8 T-cells 
derived from blood expressed more perforin compared to virus-specific LN CD8 T-cells 
in all subjects (Figure 20). Of interest, CP in this cohort expressed high amounts of 
perforin, an attribute of elite control of viral replication, yet these subjects remain 
progressors.  It is important to understand why perforin in these subjects does not 
correlate with protection. Preliminary data from the Reyes-Teran group (Mexico City) 
has found differences in HLA protective alleles in subjects from Central America 
compared to what is found in the literature (data not published).  Differences in genetic 
background could explain the discrepancies between our two cohorts.  Further work 
dissecting these differences is necessary to clarify the lack of control in these subjects.     
To determine differences in expression of inhibitory receptors in HIV-specific LN 
and blood CD8 T-cells, we measured expression of PD-1, CD160 and 2B4.  We began by 
measuring single expression of these receptors.  Gag-specific LN CD8 T-cells in the LN 
from CP expressed significantly more PD-1 (p<0.01) than in the blood.  In agreement to 
previously published data (MD et al., 2009), expression of PD-1 is decreased after 
initiation of ART (Figure 21A).  This change in expression appears to be HIV-specific as 
PD-1 expression on EBV-specific LN CD8 T-cells remains high in all subjects (Figure 
21B).  One possible explanation is that removal of HIV viral antigen in LN after ART 
induces HIV-specific cell death, whereas EBV-specific cells are unaffected.  The 
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proportion of HIV-Gag-specific CD160+ LN CD8 T-cells was significantly lower in CP 
(p<0.01) compared to blood, but not ART or HIV negative subjects (Figure 21C).  There 
was no difference in expression of CD160 on EBV-specific CD8 T-cells from blood and 
LN (Figure 21D).  Expression of 2B4 on HIV-Gag and EBV-specific CD8 T-cells from 
blood and LN was similar in CP, ART and HIV negative subjects (Figure 21E and F).   
 
Co-expression of PD-1, CD160 and 2B4 on blood and lymph node CD8 T-cells 
A high proportion of cytolytic CD160+2B4+ CD8 T-cells were found in the blood 
of elite controllers (chapter 3).  This population of cells is not commonly found in CP; 
instead they have a significant proportion of PD1+CD160+2B4+ CD8 T-cells believed to 
be exhausted.  To determine if these relationships between perforin expression and 
patterns of inhibitory receptor expression were different between blood and lymph node, 
we analyzed co-expression of these inhibitory receptors by HIV-Gag and EBV-specific 
CD8 T cells.   In this cohort, HIV-Gag and EBV-specific CD8 T-cell responses in blood 
and LN from CP and ART subjects were primarily divided into PD-1+CD160+2B4+ and 
PD-1-CD160+2B4+ (Figure 22A and B [middle and bottom graphs]).  Lymph nodes in 
chronic progressors exhibited a higher proportion of potentially exhausted PD-
1+CD160+2B4+ virus-specific CD8 T cells compared to blood (p=0.01) (Figure 22A top 
graph, and B middle graph).  On the other hand, blood CD8 T cells had a higher 
proportion of CD160+2B4+ expression compared to LN, a population associated with 
perforin expression (chapter 3).  In contrast, a majority of the EBV-specific responses in 
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blood and LN from HIV-negative subjects were PD-1-CD160-2B4+, with smaller 
proportions also PD-1-CD160+2B4+ or negative for the three receptors (Figure 22B, top 
graph).  Unexpectedly, in contrast with our previous findings (Figure 13), there was no 
correlation between the proportion of perforin+ response and co-expression of CD160 
and 2B4 in either blood or lymph node for both HIV-Gag and EBV-specific responses 
(Figure 23).       
Dissociation between perforin and T-bet in lymph node CD8 T-cells 
Our lab and others have shown that high expression of T-bet (T-betbright) 
correlates with cytolytic activity in CD8 T-cells from blood, measured by perforin and 
granzymes (Buggert et al., 2014; Hersperger et al., 2011).  To further address differences 
between CD8 T-cells in the blood and lymph node, we examined expression transcription 
factor T-bet in HIV-Gag and EBV-specific cells.  Overall, memory CD8 T-cells in the 
lymph node express significantly lower levels of T-bet compared to blood (data not 
shown).  This is not surprising given the high proportion of effector CD8 T cells found in 
blood compared to LN.  Similarly, there is a significantly smaller proportion of HIV-
Gag-specific CD8 T cells from lymph nodes expressing T-bet compared to blood (CP: 
p<0.001, ART: p<0.01), and per-cell expression is also lower than in blood (CP: p<0.01, 
ART: p<0.01) (Figure 24A and B).  Per-cell levels of T-bet expression increase after 
ART (p<0.01) (Figure 24B).  These levels of expression were similar in EBV-specific 
CD8 T cells from HIV+ subjects (Figure 24C and D).  Similar patterns of expression 
were observed for blood and lymph node EBV-specific CD8 T cells in HIV negative 
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subjects.  However, HIV negative lymph nodes have a significantly larger population of 
EBV-specific CD8 T-cells that are T-bet+ compared to HIV+ lymph nodes (CP: p-0.05, 
ART: p=0.01) (Figure 24B).   
In agreement with previous reports, we found a significant association between 
perforin and high levels of T-bet (T-betbright) in HIV-Gag-specific CD8 T-cells from 
blood in CP.  The statistical significance is lost after initiation of ART, but the trend 
remains (Figure 25A). However, this association is lost in lymph node CD8 T-cells from 
both CP and ART (Figure 25B).  Similarly, EBV-specific CD8 T-cells from HIV 
negative and ART subjects had a strong association between perforin and T-betbright. The 
trend was the same for CP, but it did not reach statistical significance (Figure 25C).  
Whereas HIV negative lymph nodes showed the same correlation for EBV-specific CD8 
T-cells, CP and ART LN CD8 T-cells do not (Figure 25D).  Together, these data indicate 
dissociation between perforin and T-bet in lymph nodes.   
 
DISCUSSION 
It has been known since the early 1990s that lymph nodes function as a major 
reservoir during HIV infection (Pantaleo et al., 1991).  Despite successful suppression of 
HIV replication to undetectable levels, ongoing viremia can be detected at levels of 1 to 
50 copies/ml in patients (Altfeld et al., 2002; Richman et al., 2009).  Regardless of the 
effectiveness of current antiretroviral therapy, HIV remains incurable; therapy must be 
maintained for life with interruptions resulting in viral rebound and emergence of escape 
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mutants. It has become clear that it is necessary to eliminate the viral reservoir if there is 
hope for a cure.  Current efforts include the development of drugs to stimulate latently 
infected cells that would trigger clearance by the immune system in combination with 
ART (Richman et al., 2009).  But the ability of lymph node-resident immune cells, such 
as CD8 T cells, to clear infected cells remains a question important to address for this 
approach to be successful. 
Lymph nodes are important for immune reconstitution.  B cell maturation and T 
cell activation take place within the lymph nodes.  However, little is known of the state of 
immunologically important cells within these sites, and whether they can respond 
appropriately to clear infected cells.  Regulatory mechanisms such as expression of 
inhibitory receptors are in place to protect the integrity of the lymph node architecture. 
This work gives a baseline of expression of PD-1, CD160 and 2B4 in healthy lymph 
nodes.  In healthy individuals, there is a higher proportion of CD8 T cells expressing PD-
1 compared to blood CD8 T cells. One can infer that PD-1 upregulation is induced upon 
entry into the lymph node to dampen harmful responses and preserve the lymph node 
architecture.  On the other hand, there is a lower proportion in expression of 2B4 in 
lymph node CD8 T cells compared to blood CD8 T cells that can be interpreted as a way 
of dampening the cytolytic response of cytotoxic CD8 T cells while in the lymph node. 
In blood, cytotoxic CD8 T-cells are a correlate of protection against HIV in elite 
controllers.  It is possible that CD8 T cells in lymph nodes with cytolytic potential could 
be reinvigorated to kill and clear infected cells.  CD8 T cells in HIV positive lymph 
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nodes express high levels of PD-1.  Though this marker is strongly associated with T-cell 
exhaustion, its expression alone is not sufficient to render a cell exhausted.  However, 
lymphatic endothelial cells induce tolerance via the PD-1/PD-L1 pathway aiding in the 
protection of infected cells.  The majority of data available on T-cell exhaustion in the 
context of HIV infection has been gathered from peripheral blood.  In this study we 
examined CD8 T-cell exhaustion in blood and lymph nodes from a group of chronic 
progressors (CP) and HIV+ subjects on antiretroviral therapy (ART) to determine if the 
parameters observed in blood are representative of the lymph node.  
We measured expression of PD-1, CD160 and 2B4 in combination with 
functional markers IFNγ, TNF and perforin.  In accordance to a previous report (MD et 
al., 2009), we find that CD8 T-cells in lymph nodes have a high expression of PD-1 
compared to those from blood. Additionally, lymph node CD8 T-cells have a large 
population of PD-1+CD160+2B4+, previously defined as exhausted.  This population is 
significantly larger in lymph nodes than in blood, suggesting that we are underestimating 
the extent of exhaustion occurring during HIV infection.  This can have an important 
repercussion for immune reconstitution.  Additionally, this exhausted population could be 
a target for anti-PD-1/PD-L1 therapy in an effort to re-invigorate immune responses.  
Importantly, the anti-PD-1/PD-L1 blocking antibody needs to be able to access CD8 T 
cells in relevant tissues to exert its effect.  In addition, target cells need to be able to 
respond to stimulation with the desired functions.  What those desired functions are 
remains to be determined. 
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We also report that lymph nodes have small populations of CD8 T-cells 
expressing perforin.  Though there is a small proportion of cytolytic CD8 T-cells in LN, 
those cells may be enough to eliminate infected TFH cells.  The question remaining is 
whether those cells are able to reach the infected cells sequestered in B cell follicles.  
Further studies into the lymph node architecture and whether CD8 T cells can infiltrate 
the B cell follicle will be required.  Additionally, the fact that CD8 T-cells in lymph 
nodes do not express high levels of perforin does not indicate they are unable to 
upregulate its expression upon stimulation.  Transcription factor T-bet modulates perforin 
expression and suppresses expression of PD-1.  We find that 40% of lymph node CD8 T-
cells express T-bet.  However, the per-cell levels of expression are low compared to CD8 
T cells in the blood.  We have previously shown that per-cell levels (MFI) of T-bet 
expression are associated with its ability to function.  Dim levels of expression is 
associated with cytoplasmic localization of this transcription factor, whereas bright levels 
of expression associates with nuclear, therefore active, T-bet (McLane et al., 2013).  
Finding a way to induce T-bet translocation into the nucleus could be a target of 
therapeutic value.    
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Figure 14: Gating strategy for PD-1, CD160 and 2B4 expression on total, naïve and 
memory CD8 T-cells from blood and lymph node 
A) Gating scheme of Peripheral blood mononuclear cells (PBMC) identify naïve 
CD27+CD45RO-) and memory CD8 T-cells.  The same gating strategy was used on 
lymph node mononuclear cells (LNMC). Representative flow plots showing expression 
of PD-1, CD160 and 2B4 on naïve and memory CD8 T-cells from blood (B) and lymph 
75 
 
nodes (C) from an HIV chronic subject (top row), an HIV+ on therapy (ART, middle 
row) and an HIV negative individual (bottom row). 
 
Figure 15: Memory distribution of CD8 T-cells from blood and lymph nodes. 
After gating on CD3+ CD8+ lymphocytes, differential expression of CD27 and CD45RO 
was used to identify (A) naïve (CD27+CD45RO-), (B) central memory 
(CD27+CD45RO+), (C) effector memory (CD27-CD45RO+) and (D) effector (CD27-
CD45RO-) CD8 T-cells collected from blood (closed circles) and lymph nodes (open 
circles) from HIV negative (blue), chronic (red) and HIV+ on ART (orange).  Each dot 
represents a subject, bars represent the mean. Statistical differences between blood and 
lymph nodes from HIV negative subjects were calculated by a non-parametric T test.  
Statistical differences between blood and lymph nodes from chronics and ART subjects 
were calculated by paired T tests.  p values < 0.05 were considered significant.  * p<0.05, 
** p<0.01, *** p<0.001 
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Figure 16: Comparison expression of PD-1, CD160 and 2B4 on CD8 T cells from 
HIV negative, chronic progressors and ART subjects  
Memory CD8 T-cells were identified by exclusion of the naïve population 
(CD27+CD45RO-).  
(A) The percentage of memory CD8 T-cells derived from blood of HIV negative (HIV-), 
chronic progressors (CP) and HIV+ on ART (ART) expressing individual receptors. (B) 
The percentage of memory CD8 T cells derived from lymph nodes from HIV negative, 
CP and ART subjects expressing individual receptors. Each dot represents a subject. 
Error bars represent mean + SEM. Statistical analysis was carried out using one-way 
ANOVA tests (nonparametric; Kruskal-Wallis) followed by a Dunns test for multiple 
comparisons. ** p<0.01, *** p<0.001 
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Figure 17: Comparison between blood and lymph node expression of PD-1, CD160 
and 2B4 on CD8 T-cells  
Individual expression of inhibitory receptors (A) PD-1, (C) CD160 and (E) 2B4 was 
measured on memory CD8 T-cells by exclusion of the naïve CD27+CD45RO- population. 
The mean fluorescence Intensity (MFI) was used to measure per-cell levels of expression 
of (B) PD-1, (D) CD160 and (F) 2B4. Statistical differences between blood and lymph 
nodes from HIV negative subjects were calculated by a non-parametric T test.  Statistical 
differences between blood and lymph nodes from chronics and ART subjects were 
calculated by paired T tests.  p values < 0.05 were considered significant.  * p<0.05, ** 
p<0.01, *** p<0.001 
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Figure 18: Co-expression of inhibitory receptors on memory CD8 T-cells from blood 
and lymph node. 
Single expression gates for each inhibitory receptor were used in a boolean gate analysis 
to determine all possible combinations of inhibitory receptor expression on CD8 T-cells 
from blood (black bars) and lymph nodes (grey bars) from HIV negative (top graph), 
HIV chronic (middle graph) and HIV subjects on ART (bottom graph).  Each dot 
represents a subject.  Statistically significant differences were calculated using the T test 
function within the SPICE program. p values <0.05 were considered significant. * 
p<0.05, ** p<0.01, *** p<0.001 
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Figure 19: Gating scheme for detection of virus-specific responses. 
Representative flow cytometry plots showing expression of IFNγ, TNF and perforin on 
CD8 T-cells from (A) blood and (B) lymph node.  A no-stimulation condition was used 
as a negative control to identify responses above background.  Naïve CD8 T-cells were 
used to determine gate placements. 
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Figure 20: Functional profile of HIV and EBV-specific CD8 T cells.  
Proportion of cytokine and perforin production by CD8 T cells in response to peptide 
pool stimulation of PBMCs (black bars) and LNMCs (grey bars) with a Gag-PTE peptide 
pool or an EBV pool containing peptides derived from lytic proteins. (A) HIV Gag-
specific response from chronic progressors (top graph) and HIV+ subjects on ART 
(bottom graph). (B) EBV-specific response from HIV negative (top graph), chronic 
progressors (middle graph) and HIV+ subjects on ART (bottom graph). Bars represent 
mean of expression: each dot represents a subject. * p<0.05, ** p<0.01, *** p<0.001  
 
 
 
 
A) 
B) 
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Figure 21: Comparison between blood and lymph node expression of PD-1, CD160 
and 2B4 on CD8 T-cells  
Individual expression of inhibitory receptors was measured on Gag-specific and EBV-
specific CD8 T cells. PD-1 expression on (A) HIV-Gag-specific and (B) EBV-specific 
CD8 T cells from blood (grey bar) and lymph node (white bar). CD160 expression on (C) 
HIV-Gag-specific and (D) EBV-specific CD8 T cells from blood (dark gray bar) and 
lymph node (white bar). 2B4 expression on (E) HIV-Gag-specific and (F) EBV-specific 
CD8 T cells from blood (dark gray bar) and lymph node (white bar) was measured on 
Gag-specific CD8 T-cells. Statistical differences between blood and lymph nodes from 
HIV negative subjects were calculated by a non-parametric T test.  Statistical differences 
between blood and lymph nodes from chronics and ART subjects were calculated by 
paired T tests.  p values < 0.05 were considered significant.  * p<0.05, ** p<0.01, *** 
p<0.001 
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Figure 22: Co-expression of inhibitory receptors on memory CD8 T-cells from blood 
and lymph node. 
Single expression gates for each inhibitory receptor were copied from the total memory 
population.  Single expression gates from cells responding to peptide pool stimulation 
were then used in a boolean gate analysis to determine all possible combinations of 
inhibitory receptor expression on CD8 T-cells from blood (black bars) and lymph nodes 
(grey bars) (A) HIV-Gag-specific responses from HIV chronic subjects (top graph) and 
HIV subjects on ART (bottom graph).  (B) EBV-specific responses from HIV negative 
(top graph), HIV chronic progressors (middle graph) and HIV subjects on ART.  Each 
dot represents a subject.  Statistically significant differences were calculated using the T 
test function within the SPICE program. p values <0.05 were considered significant. * 
p<0.05, ** p<0.01, *** p<0.001 
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Figure 23. Association between perforin and co-expression of CD160 and 2B4. 
Correlation between the percent of the (A) HIV-specific and (B) EBV-specific CD8 T-
cell response that is perforin+ and the percent of the response co-expressing inhibitory 
receptors. HIV negative (blue dots), CP (red dots), EC (green dots).  Spearman R and p 
value of correlations are depicted in the upper right corner of each graph.  Lines represent 
linear regression.  
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Figure 24: T-bet expression in Gag and EBV-specific CD8 T cells from blood and 
lymph node. 
Expression transcription factor T-bet was measured on (A) Gag and (C) EBV-specific 
CD8 T-cells. The mean fluorescence Intensity (MFI) was used to measure per-cell levels 
of expression of T-bet on (B) Gag and (D) EBV-specific CD8 T cells. Statistical 
differences between blood and lymph nodes from HIV negative subjects were calculated 
by a non-parametric T test.  Statistical differences between blood and lymph nodes from 
chronics and ART subjects were calculated by paired T tests.  p values < 0.05 were 
considered significant.  * p<0.05, ** p<0.01, *** p<0.001 
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Figure 25. Association between high expression of T-bet and co-expression of CD160 
and 2B4. 
Correlation between the percent of the (A) HIV-specific and (B) EBV-specific CD8 T-
cell response that is perforin+ and the percent of the response co-expressing inhibitory 
receptors. HIV negative (blue dots), CP (red dots), EC (green dots).  Spearman R and p 
value of correlations are depicted in the upper right corner of each graph.  Lines represent 
linear regression.  
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CHAPTER 5: DISCUSSION 
This body of work focused on the characterization of T cell exhaustion in the 
context of HIV infection.  Immune dysfunction during HIV infection emerges as a 
consequence of prolonged antigen stimulation and immune activation, where cells 
gradually become less functional and eventually are unable to suppress HIV viral 
replication.  In the long run, the destruction of the immune system is so severe the 
infected individual is left susceptible to opportunistic infections.  Understanding the 
mechanisms of T cell exhaustion has become an area of extensive research.  T cell 
exhaustion has been linked to expression of a variety of inhibitory receptors including 
PD-1, CD160, 2B4, CTLA-4, Lag-3, BTLA, Tim-3 and others.  Previous work has shown 
that co-expression of these receptors identify exhausted populations in animal models and 
during chronic human disease (Blackburn et al., 2008; Peretz et al., 2012; Tian et al., 
2015; Yamamoto et al., 2011).  However, there is also evidence that some of these 
receptors are also involved with effector function, namely CD160 and 2B4.  We used 
polychromatic flow cytometry to measure expression of PD-1, CD160, 2B4 and Lag-3 in 
the context of controlled HIV infection in elite controllers.  We chose these receptors 
based on a previously performed microarray analysis of exhausted T cells showed a high 
association between expression of CD160, 2B4 and Lag-3 with PD-1.  
Elite controllers are HIV infected individuals capable of suppressing viral 
replication without the need for ART.  These subjects have highly functional HIV-
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specific CD8 T cells with high cytolytic potential.  Our question was whether these 
subjects exhibited signs of T cell exhaustion as measured by PD-1, CD160 and 2B4.   
Interestingly, we found that elite controllers exhibit signs of T cell exhaustion.  
We found a population of HIV-specific PD-1+CD160+2B4+ HIV-specific CD8 T cells not 
common in chronic progressors (Pombo et al., 2015).  These findings are consistent with 
reports that elite controllers experience ongoing replication in lymph nodes that is 
undetectable in serum (Moir, Chun, & Fauci, 2011).  We also report that elite controllers 
have a population of CD160+2B4+ HIV-specific CD8 T cell not found in chronic 
progressors (Pombo et al., 2015).  Co-expression of CD160 and 2B4 is strongly 
associated with cytolytic potential.  Several lines of evidence demonstrate that CD160 
and 2B4 play a role in enhancing cytotoxic activity (Cai & Freeman, 2009; Meinke & 
Watzl, 2013; Nikolova et al., 2002; Rey et al., 2006; Saborit-Villarroya et al., 2008).  We 
propose that expression of PD-1 in the triple-positive exhausted population modulates the 
activating functions of CD160 and 2B4.  More insight into downstream targets of PD-1 
signaling could point to a molecule involved in CD160 and/or 2B4 signaling.  
Alternatively, PD-1 could modulate signals directly affecting perforin expression or 
degranulation.    
 We also report that expression of inhibitory receptors measured in the blood 
underestimate levels of expression in lymph nodes.  We report that there is a greater 
proportion of PD-1+CD160+2B4+ CD8 T cells in lymph nodes compared to blood.  In 
addition, perforin expression is significantly reduced within these tissues.  Unexpectedly, 
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a previously established relationship between perforin expression and T-bet was not 
observed in lymph nodes.  This implies the possibility of another factor controlling 
perforin expression in this tissue, such as another T-box transcription factor Eomes.  
Increased expression of Eomes has been linked to T-cell exhaustion in the context of HIV 
(Buggert et al., 2014).   
 Lymph nodes play an important role in immunity; they harbor the majority of the 
body’s lymphocytes and it is where antigen presentation and maturation of B and T cells 
takes place.  However, lymph nodes also play a vital role in HIV infection.  Several 
groups have shown that lymph nodes harbor the HIV reservoir and are the main source of 
HIV replication.  The inability to clear infected cells in the lymph node and eliminate the 
HIV reservoir forces HIV+ subjects to remain on therapy for a lifetime.  Any lapses or 
regiment interruption can result in re-emergence of virus and evolutionary mutation 
rendering the virus drug resistant (Richman et al., 2009).  In addition, concern for toxic 
effects of long-term antiretroviral therapy is pushing the field to find a cure.  Some 
studies point to increased rates of heart disease, diabetes, liver disease, and forms of 
cancer in aging HIV-infected patients who are receiving treatment (Richman et al., 2009) 
Furthermore, with infections in adolescents on the rice, the number of years a person will 
spend on ART has increased on average by 20 years.  The goal of being able to stop ART 
without viral rebound is made difficult by the presence of the immune reservoir.  
Understanding T cell exhaustion in lymph nodes is important in the development of 
therapeutics aimed at re-invigorating CD8 T cells at the sites where infected cells live 
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(i.e. the lymph node).  For these therapies to be effective, they must take into account the 
microenvironment in which the T-cell will be exerting its function.  
In conclusion, this work shows that expression of inhibitory receptors does not 
always signify exhaustion; CD160 and 2B4 were associated with perforin expression in 
elite controllers.  However it is clear that PD-1 plays an important role inhibiting CD8 T-
cells, but expression of this receptor alone does not control CD8 T-cell.  We also showed 
that it is important to measure exhaustion directly in tissues important for disease, as 
blood is not always a good surrogate.  
Though we did not measure other inhibitory markers in this thesis, a 
comprehensive understanding of their role in immune modulation and exhaustion needs 
to be performed.  The role inhibitory markers such as CTLA, TIM-3, Lag-3 in exhaustion 
of CD4 T cells and NK cells demonstrate the complexity involved in immunomodulation. 
Additionally, further understanding on the regulatory pathway triggered upon interaction 
of these receptors with their ligands is important for continued development of strategies 
involved in reinvigorating exhausted cells. Blocking studies in-vivo using the SIV model 
of infection of non-human primates should be more fully develop to elucidate the 
unintended consequences of manipulating inhibitory receptors. My work, along with 
others, show the importance of concentrating significant efforts in looking at secondary 
lymphoid tissues, particularly lymph nodes, when developing new vaccine platforms or 
therapies 
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